

**Funding Opportunities Monthly Edition  
July 2021 Due Dates**

## Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in July 2021. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
096961	<a href="#">AMENDMENT -- SBSA -- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Concept Award Program – Fiscal Year 2022</a>	National Cancer Institute/NIH/DHHS	75N91020R00043	23-Jul-2021	Not Specified

Contact Name	Tiffany Chadwick
Contact Telephone	
Contact Email	<a href="mailto:tiffany.chadwick@nih.gov">tiffany.chadwick@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	23-Jul-2021
Synopsis	<p>The National Cancer Institute is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. This new high-risk, high-reward Innovative Concept Award solicitation is intended to encourage small businesses to work on bold and “out of the box” ideas rather than just the tried and tested approaches to make a significant impact in the prevention, diagnosis, treatment, and care of these cancers. For the purpose of this solicitation, rare cancers include all the cancers listed by the NIH Genetics and Rare Diseases Information Center. The list can be found here: <a href="https://rarediseases.info.nih.gov/diseases/diseases-by-category/1/rare-cancers">https://rarediseases.info.nih.gov/diseases/diseases-by-category/1/rare-cancers</a> Preliminary data is not required; however, the idea should have a sound scientific premise either based on the offeror’s own research or literature evidence. Proposals will need to identify an anticipated product that will be developed and clearly lay out the anticipated development path. Proposals will need to clearly identify the clinical problem and cancer type(s) that the proposal will focus on with adequate justification. In addition, the offerors should propose experiments to obtain initial de-risking and proof-of-concept data. Awards will also include requirements to enhance entrepreneurship skills and to develop or refine a business model and commercialization plan. This solicitation is a pilot ‘Phase 0’ Concept Award program that could serve as a pipeline for the federal Small Business Innovation Research (SBIR) program. Background for the SBIR program can be found in the Small Business Administration’s policy directive found here: <a href="https://www.sbir.gov/sites/default/files/SBIR-STTR_Policy_Directive_2019.pdf">https://www.sbir.gov/sites/default/files/SBIR-STTR_Policy_Directive_2019.pdf</a> . This is a total small business set-aside solicitation. Only proposals from eligible small businesses will be considered for award. This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. To be eligible as a small business, the business concern may have no more than 500 employees, including the employees of its Affiliates. See 13 C.F.R. § 121.702. Other requirements apply, as well – see the SBA’s SBIR Policy Directive for further eligibility requirements - <a href="https://www.sbir.gov/sites/default/files/SBIR-STTR_Policy_Directive_2019.pdf">https://www.sbir.gov/sites/default/files/SBIR-STTR_Policy_Directive_2019.pdf</a>. The initial solicitation for the NCI SBIR Innovative Concept Award Program is anticipated to be made available in or around July/August, 2020. This solicitation is</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		anticipated to have a closing date in early/mid December for receipt of proposals, with an interim date for submission and consideration of white papers which will allow the NCI to provide feedback on whether or not the proposed idea falls within the scope of what this solicitation is seeking. NOTE – SBIR / STTR GRANT OPPORTUNITIES Other SBIR and STTR contract and grant opportunities are also available. Companies are encouraged to review <a href="https://sbir.nih.gov/funding">https://sbir.nih.gov/funding</a> . For general information regarding the NCI SBIR Program, please refer to <a href="https://sbir.cancer.gov/">https://sbir.cancer.gov/</a> . Additional beta.sam.gov information Notice Id eb4c4db179ee47c0b6085e30cdc35e52 Source <a href="https://beta.sam.gov/opp/eb4c4db179ee47c0b6085e30cdc35e52/view">https://beta.sam.gov/opp/eb4c4db179ee47c0b6085e30cdc35e52/view</a> Note: This link might not be valid after archive date below. Archive Date 12/31/2020			
082789	<a href="#">Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-287	09-Jul-2021	2,000,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Dr. Shannon K. Hughes 240-276-6224 <a href="mailto:shannon.hughes@nih.gov">shannon.hughes@nih.gov</a>  <a href="#">Link to program URL</a> 09-Jul-2021 , 15-Nov-2021			
	Synopsis	The National Cancer Institute’s (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.			
100261	<a href="#">Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-20-313	09-Jul-2021	1,025,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website	Tracy G. Lively, Ph.D. 240-276-5944 <a href="mailto:livelyt@mail.nih.gov">livelyt@mail.nih.gov</a>  			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jul-2021 , 08-Oct-2021 , 14-Feb-2022 , 11-Jun-2022 , 11-Oct-2022 , 14-Feb-2023 , 10-Jul-2023 , 10-Oct-2023</p> <p>Synopsis            Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this FOA supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this FOA supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this FOA must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.</p>				
100262	<a href="#">Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-20-314	09-Jul-2021	750,000 USD
	<p>Contact Name Tracy G. Lively, Ph.D.</p> <p>Contact Telephone 240-276-5944</p> <p>Contact Email <a href="mailto:livelyt@mail.nih.gov">livelyt@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jul-2021 , 08-Oct-2021 , 14-Feb-2022 , 11-Jun-2022 , 11-Oct-2022 , 14-Feb-2023 , 10-Jul-2023 , 10-Oct-2023</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.</p>			

090518	<a href="#">RFA-CA-20-028 -- Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-028	30-Jun-2021 [Optional][LOI/Pre-App]	275,000 USD
--------	---	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Michelle Mollica, Ph.D., M.P.H., R.N., O.C.N.,
Contact Telephone	240-276-7621
Contact Email	<a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021
Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Specifically, this FOA solicits mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
090505	<a href="#">RFA-CA-20-027 -- Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-027	30-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Michelle Mollica, Ph.D., M.P.H., R.N., O.C.N.,</p> <p>Contact Telephone: 240-276-7621</p> <p>Contact Email: <a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Specifically, this FOA solicits mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.</p>				
087537	<a href="#">Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-20-074	13-Jul-2021	450,000 USD
	<p>Contact Name: Sumana Dey, Ph.D.</p> <p>Contact Telephone: 240-276-5748</p> <p>Contact Email: <a href="mailto:sumana.dey@nih.gov">sumana.dey@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 13-Jul-2021 , 26-Oct-2021 , 28-Feb-2022 , 11-Jul-2022 , 28-Oct-2022</p> <p>Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this FOA should be on the adaption and clinical</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.</p>			
077749	<a href="#">Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-18-947	11-Jul-2021	1,250,000 USD
	Contact Name	Abhi Rao, Ph.D.			
	Contact Telephone	240-276-5715			
	Contact Email	<a href="mailto:abhi.rao@nih.gov">abhi.rao@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	11-Jul-2021			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies, or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for liquid biopsies, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.</p>			
103025	<a href="#">RFA-CA-21-036 -- SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward</a>	National Cancer Institute/NIH/DHHS	RFA-CA-21-036	06-Jul-2021 [Optional][LOI/Pre-	4,000,000 USD



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<a href="#">Commercialization (R44 Clinical Trial Optional)</a>				App]	
	<p>Contact Name   Jonathan Franca-Koh, PhD, MBA</p> <p>Contact Telephone   240-618-0984</p> <p>Contact Email   <a href="mailto:francakohjc@mail.nih.gov">francakohjc@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   06-Jul-2021 [Optional][LOI/Pre-App], 06-Aug-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.</p>				
045115	<a href="#">Short-Term Scientist Exchange Program</a>	National Cancer Institute/NIH/DHHS		01-Jul-2021	Not Specified
	<p>Contact Name   Dr. Vidya Vedham</p> <p>Contact Telephone   240-276-7272</p> <p>Contact Email   <a href="mailto:NCICenterforGlobalHe@mail.nih.gov">NCICenterforGlobalHe@mail.nih.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL  </p> <p>Deadline Dates (ALL)   01-Jul-2021 , 01-Oct-2021</p> <p>Synopsis   The Short-Term Scientist Exchange Program (STSEP) promotes collaborative research between researchers at the National Cancer Institute (NCI) and scientists from low-, middle-, and upper-middle income countries.</p>				
098641	<a href="#">NCI Clinical and Translational Exploratory/Developmental</a>	National Cancer	PAR-20-292	21-Jun-2021	275,000

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Studies (R21 Clinical Trial Optional)</a>	Institute/NIH/DHHS			USD
	<p>Contact Name   William C. Timmer, Ph.D</p> <p>Contact Telephone   240-276-6130</p> <p>Contact Email   <a href="mailto:william.timmer@nih.gov">william.timmer@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   21-Jun-2021 , 20-Jul-2021 , 20-Oct-2021 , 17-Dec-2021 , 22-Feb-2022 , 21-Jun-2022 , 21-Jun-2022 , 20-Jul-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).</p>				
103284	<a href="#">RFA-CA-21-025 -- Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-21-025	30-Jun-2021 [Optional][LOI/Pre-App]	3,750,000 USD
	<p>Contact Name   Henry Rodriguez, MS, PhD, MBA</p> <p>Contact Telephone   240-781-3370</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:rodriguez@mail.nih.gov">rodriguez@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis                      This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science. This FOA solicits applications for multidisciplinary Proteogenomic Translational Research Centers (PTRCs). PTRCs are intended to function as an interactive group focused on applying standardized state-of-the-art proteomic and genomic approaches to understand tumor biology in clinically relevant research projects related to treatment response. Projects should focus on the proteogenomic aspects of understanding drug response and resistance by generating and testing hypothesis using preclinical cancer models and/or human cancer samples, followed by validation using human biospecimens from clinical trials. Proposed projects are expected to be conducted in collaboration with clinical researchers, including molecular oncologists. It is envisioned that these projects will facilitate a rational approach to target cancer-related pathways and improve outcomes for patients with cancer. PTRCs will interact with additional CPTAC Centers that include: Proteogenomic Data Analysis Centers (PGDACs, to be supported by RFA-CA-21-024; U24) that will conduct integrative analyses of data across the entire proteomes and genomes of human tumors to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level; and Proteome Characterization Centers (PCCs, to be supported by RFA-CA-21-023; U24) that will use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically characterized samples. These samples (human biospecimens and preclinical models) will be provided by the NCI.</p>				
081437	<a href="#">Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-251	08-Jul-2021	Not Specified
	<p>Contact Name Wendy Wang, Ph.D. M.Sc.</p> <p>Contact Telephone 240-276-7117</p> <p>Contact Email <a href="mailto:wangw@mail.nih.gov">wangw@mail.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Jul-2021 , 08-Nov-2021			
	Synopsis	<p>The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.</p>			
103296	<a href="#">RFA-RM-21-020 -- Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-RM-21-020	15-Jun-2021 [Optional][LOI/Pre-App]	600,000 USD
	Contact Name	Jerry Li, M.D.,Ph.D.			
	Contact Telephone	240-276-6210			
	Contact Email	<a href="mailto:DruggableGenome@mail.nih.gov">DruggableGenome@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2021 [Optional][LOI/Pre-App], 15-Jul-2021			
	Synopsis	<p>The overarching goal of this funding opportunity announcement (FOA) for the Common Fund program "Illuminating the Druggable Genome" (IDG;<a href="https://commonfund.nih.gov/idg/">https://commonfund.nih.gov/idg/</a>) is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the IDG consortium's Knowledge Management Center (KMC) as well as the broader IDG Consortium. Awards will support the IDG Consortium by: (1) developing and deploying tools to enhance the community's ability to process, analyze, and visualize IDG data, (2) prioritizing new data resources and methods to be incorporated into Pharos(<a href="https://pharos.nih.gov/idg/index">https://pharos.nih.gov/idg/index</a>)that will strengthen predictions about physiological and disease associations around IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels), and (3) developing methods to prioritize IDG-eligible understudied proteins for deeper study using experimental assays both developed within the IDG pipeline or by the larger community. The IDG consortium's purpose is to facilitate the unveiling of the functions of selected understudied proteins in the Druggable Genome using experimental and informatics approaches. Currently, this research consortium is composed of multiple Data and Resource Generation Centers (DRGCs), a Knowledge</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Management Center (KMC), and a Resource Dissemination and Outreach Center (RDOC). This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (<a href="http://commonfund.nih.gov/">http://commonfund.nih.gov/</a>) through the NIH Office of the NIH Director, Office of Strategic Coordination (<a href="https://dpcpsi.nih.gov/">https://dpcpsi.nih.gov/</a>). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Cancer Institute (NCI/NIH), (<a href="https://www.cancer.gov">https://www.cancer.gov</a>) on behalf of the NIH.</p>			
081438	<a href="#">Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-252	08-Jul-2021	275,000 USD
	Contact Name	Wendy Wang, Ph.D. M.Sc.			
	Contact Telephone	240-276-7117			
	Contact Email	<a href="mailto:wangw@mail.nih.gov">wangw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Jul-2021 , 08-Nov-2021			
	Synopsis	<p>The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.</p>			
081994	<a href="#">Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-264	09-Jul-2021	Not Specified
	Contact Name	Sudhir Srivastava, Ph.D., MPH			
	Contact Telephone	240-276-7028			
	Contact Email	<a href="mailto:srivasts@mail.nih.gov">srivasts@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 09-Jul-2021 , 10-Dec-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.</p>				
103914	<p><a href="#">RFA-CA-21-032 -- Coordinating Center for Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U24 Clinical Trial Not Allowed)</a></p>	National Cancer Institute/NIH/DHHS	RFA-CA-21-032	14-Jun-2021 [Optional][LOI/Pre-App]	4,375,000 USD
	<p>Contact Name Frank M. Perna, Ed.D., Ph.D.</p> <p>Contact Telephone 240-276-6782</p> <p>Contact Email <a href="mailto:pernafm@mail.nih.gov">pernafm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute will support a Coordinating Center (CC) to facilitate coordination across the new Exercise and Nutrition Interventions to Improve Cancer Treatment-related Outcomes awardee sites (see U01 awards supported under companion RFA-CA-21-031). This CC will support three to five anticipated cooperative agreement (U01) project sites focused on the conduct of exercise and medical nutrition clinical trials to improve cancer treatment-related outcomes. The CC's primary mission will include collaborative scientific contribution and entail administrative and communication responsibilities. The activities and responsibilities include, but are not limited to, fostering collaboration among transdisciplinary scientific teams across U01 research sites, facilitating identification and collection of common data across U01 sites for use in pilot projects, participating in cross U01 site pilot projects and leading data analyses, exploring opportunity for novel data collection, examining common research questions across U01 sites, and</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					providing communication and logistical support for annual in-person meetings of the U01 project sites and other cross-site virtual meetings of U01 investigators. The CC will also develop and execute a platform to monitor progress and facilitate evaluation of the initiative across U01 project sites. The awardee will participate in an Exercise and Nutrition to Improve Cancer Treatment-related Outcomes (ENICTO) cooperative agreement consortium.
103913	<a href="#">RFA-CA-21-031 -- Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-21-031	14-Jun-2021 [Optional][LOI/Pre-App]	4,375,000 USD
	Contact Name	Frank M. Perna, Ed.D., Ph.D.			
	Contact Telephone	240-276-6782			
	Contact Email	<a href="mailto:pernafm@mail.nih.gov">pernafm@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021			
	Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) seeks to support exercise and/or medical nutrition intervention research designed to improve cancer treatment-related outcomes for therapies delivered with curative or life-extending intent to cancer survivors. Projects may include either pediatric or adult cancer patient populations and must identify a treatment-related outcome as a primary endpoint and specify a relevant patient-reported secondary outcome(s). Priority will be given to studies with direct clinical relevance and translational potential. Responsive applications will fill a research gap concerning the efficacy of specific exercise and dietary approaches to improve cancer treatment-related outcomes. Information gained should improve behavioral intervention protocols for cancer survivors undergoing cancer treatment and may also generate feasibility information concerning translation into clinical care. Awardees will participate in an Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium.			
096068	<a href="#">Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-796	16-Jul-2021	Not Specified
	Contact Name	Narasimhan Danthi, Ph.D.			
	Contact Telephone	301-435-5170			
	Contact Email	<a href="mailto:ndanthi@mail.nih.gov">ndanthi@mail.nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jul-2021			
	Synopsis	This Notice of Special Interest is a reissue of NOT-HL-19-678. The purpose of this Notice of Special Interest is to inform potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest in exploring bold, new bioengineering approaches or concepts, including computationally-efficient methods, that are important to a substantive heart, lung, blood or sleep area, and in supporting the early phases of these innovative bioengineering projects which are, in turn, expected to transition into research to translate them into practice, technologies, or commercial products.			
085482	<a href="#">RFA-HL-20-024 -- Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-024	09-Jun-2021 [Optional][LOI/Pre-App]	500,000 USD
	Contact Name	Kathleen Rousche, Ph.D.			
	Contact Telephone	301-827-7981			
	Contact Email	<a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.			
085480	<a href="#">RFA-HL-20-022 -- Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-022	09-Jun-2021 [Optional][LOI/Pre-App]	600,000 USD
	Contact Name	Margaret Ochocinska, PhD			
	Contact Telephone	301-827-8285			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:ochocinm@mail.nih.gov">ochocinm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption.</p>				
085481	<p><a href="#">RFA-HL-20-023 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-023	09-Jun-2021 [Optional][LOI/Pre-App]	700,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email <a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.</p>				
085485	<p><a href="#">RFA-HL-20-028 -- Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)</a></p>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-028	09-Jun-2021 [Optional][LOI/Pre-App]	500,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<a href="#">Allowed</a> )					
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email <a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				
085483	<a href="#">RFA-HL-20-027 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-027	09-Jun-2021 [Optional][LOI/Pre-App]	700,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email <a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.</p>				
097524	<a href="#">Investigator-Initiated Research on Genetic Counseling Processes and Practices (R21 Clinical Trial Optional)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-049	08-Jun-2021 [Optional][LOI/Pre-App]	400,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Nicole Lockhart</p> <p>Contact Telephone   301-385-1622</p> <p>Contact Email   <a href="mailto:lockhani@mail.nih.gov">lockhani@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021</p> <p>Synopsis   The purpose of this initiative is to support targeted studies on genetic counseling processes and practices in genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Applications will assess, innovate, scale, and/or research the implementation of novel genetic counseling practices to address the need for more healthcare professionals trained in genetic counseling; the uneven access to in-person genetic counseling across U.S. health care systems; and the challenges of effective and efficient communication of genomic findings to clinicians, patients, and families.</p>				
096750	<p><a href="#">Notice of Special Interest (NOSI): Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)</a></p>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-20-059	02-Jul-2021	Not Specified
	<p>Contact Name   Diane Post, Ph.D.</p> <p>Contact Telephone   240-627-3348</p> <p>Contact Email   <a href="mailto:postd@niaid.nih.gov">postd@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   02-Jul-2021</p> <p>Synopsis   NIAID is issuing this Notice of Special Interest (NOSI) to highlight very specific and limited needs for Competitive Revision applications to active NIAID grants in order to further build the infrastructure that NIAID needs to support the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) research response. This NOSI replaces NOT-AI-20-034 which was rescinded with this issuance of this Notice.</p>				
100348	<p><a href="#">Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed)</a></p>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21-037	28-Jul-2021	100,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Paula S. Strickland, Ph.D., MPH</p> <p>Contact Telephone 240-669-2922</p> <p>Contact Email <a href="mailto:pstricklan@mail.nih.gov">pstricklan@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-Jul-2021 , 28-Jul-2022 , 28-Jul-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from research institutions in low- to middle-income countries (LMIC) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The ultimate goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in low to middle-income countries.</p>				
088718	<a href="#">International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-108	15-Jul-2021	625,000 USD
	<p>Contact Name Glen C. McGugan, Jr., Ph.D.</p> <p>Contact Telephone 240-627-3314</p> <p>Contact Email <a href="mailto:gm233g@nih.gov">gm233g@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021 , 19-Aug-2021 , 15-Jul-2022 , 19-Aug-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of high-priority, regionally relevant infectious disease research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification). Eligibility status of applicant organizations will be determined by this World Bank Classification list at application submission date.</p>				
102836	<a href="#">RFA-AI-21-020 -- Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-020	02-Jun-2021 [Optional][LOI/Pre-App]	900,000 USD
	Contact Name Steve Tsang, PhD				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-627-3330</p> <p>Contact Email   <a href="mailto:AI-DSFOAinquiries@nih.gov">AI-DSFOAinquiries@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   02-Jun-2021 [Optional][LOI/Pre-App], 02-Jul-2021 , 18-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022 , 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. This contrasts with exploratory (R21) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.</p>				
102837	<a href="#">RFA-AI-21-035-- Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-035	02-Jun-2021 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name   Steve Tsang, PhD</p> <p>Contact Telephone   240-627-3330</p> <p>Contact Email   <a href="mailto:AI-DSFOAinquiries@nih.gov">AI-DSFOAinquiries@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   02-Jun-2021 [Optional][LOI/Pre-App], 02-Jul-2021 , 18-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022 , 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge. This contrasts with early-stage development (U01) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.</p>			
102838	<a href="#">RFA-AI-21-021 -- Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated diseases (U24 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-021	02-Jun-2021 [Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Steve Tsang, PhD			
	Contact Telephone	240-627-3330			
	Contact Email	<a href="mailto:AI-DSFOAinquiries@nih.gov">AI-DSFOAinquiries@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Jun-2021 [Optional][LOI/Pre-App], 02-Jul-2021 , 18-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022 , 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge. This contrasts with early-stage development (U01) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.</p>			
103116	<a href="#">RFA-AI-21-009 -- Mechanisms of HIV Resistance to Broadly</a>	National Institute of Allergy and	RFA-AI-21-009	30-Jun-2021	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Neutralizing Antibodies (bNAbs) (U01 Clinical Trial Not Allowed)</a>	Infectious Diseases/NIH/DHHS		[Optional][LOI/Pre-App]	Specified
	<p>Contact Name   Stephen Smiley, PhD</p> <p>Contact Telephone   240-627-3071</p> <p>Contact Email   <a href="mailto:stephen.smiley@nih.gov">stephen.smiley@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis   This funding opportunity announcement (FOA) encourages multidisciplinary teams to characterize mechanisms that impact resistance to HIV broadly neutralizing antibodies (bNAbs) and develop strategies to prevent and overcome HIV resistance to bNAbs.</p>				
103192	<a href="#">RFA-AI-21-012 -- Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-012	05-Jul-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Gerard M. Lacourciere, Ph.D.</p> <p>Contact Telephone   301-761-7477</p> <p>Contact Email   <a href="mailto:gerard.lacourciere@nih.gov">gerard.lacourciere@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jul-2021 [Optional][LOI/Pre-App], 04-Aug-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages exploratory and developmental bi-phasic research. Applications are solicited to support the understanding of post-transcriptional regulation of intact and defective HIV RNA and to develop therapeutic strategies to alter RNA post-transcriptional modifications as a potential therapeutic platform for inhibiting HIV replication.</p>				
103355	<a href="#">RFA-AI-21-018 -- Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-018	05-Jul-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name   Gerald B. Sharp, Dr.P.H.				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-627-3217</p> <p>Contact Email   <a href="mailto:GSharp@niaid.nih.gov">GSharp@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jul-2021 [Optional][LOI/Pre-App], 04-Aug-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that use innovative technology to conduct epidemiologic studies of large cohorts of U.S. populations at high risk of HIV acquisition: men who have sex with men (MSM), people who inject drugs (PWID), and transgender women and men, focusing especially on the minority and age groups at highest risk of HIV transmissions. The major goal is to support investigators who will use innovative electronic methods to recruit and retain large samples of persons at high risk of HIV acquisition, comparing those who become HIV-positive to those who do not, and optionally to develop and test digitally-delivered interventions that promote HIV risk reduction to reduce HIV-incidence.</p>				
103329	<a href="#">AMENDMENT--SBSA -- DMID Regulatory Affairs Support</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NIHA175N93021R00010	28-Jul-2021	Not Specified
	<p>Contact Name   Ignacio Reyes</p> <p>Contact Telephone   301-435-7574</p> <p>Contact Email   <a href="mailto:ignacio.reyes@nih.gov">ignacio.reyes@nih.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL  </p> <p>Deadline Dates (ALL)   28-Jul-2021</p> <p>Synopsis   Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), strives to understand, treat and ultimately prevent the myriad of infectious, immunologic, and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control and prevent diseases caused by virtually all infectious agents other than Human Immunodeficiency Virus. This includes basic and applied research to develop and evaluate therapeutics, vaccines, and diagnostics, which is funded through a variety of research grants and contracts. Developing and testing new vaccines and therapies have historically been a major focus of the research supported by the DMID. Much of this research is devoted to addressing critical public health needs, such as those related to emerging and reemerging infectious diseases (e.g., SARS-CoV-2, Ebola, influenza, etc.), as well as those supporting the evaluation of the safety and efficacy of vaccine and therapeutic candidates against potential agents of bioterrorism, including NIAID priority</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

biodefense pathogens (<https://www.niaid.nih.gov/research/emerging-infectiousdiseases-pathogens>). In order to ensure that the development, testing and manufacture of products evaluated under DMID-supported clinical research are executed with a rigor that will support licensure or emergency use authorization by the Food and Drug Administration (FDA) or other regulatory authorities, DMID supports an infrastructure to provide regulatory assistance in the development and testing of these products. Currently, DMID sponsors approximately 100 Investigational New Drug Applications (INDs) or Master Files (MFs) which span more than 200 clinical trials. This includes both multicenter trials and single center studies, and encompasses Phase 1, 2, and 3 clinical trials performed at both domestic and foreign sites. DMID files approximately 10-20 new INDs each year, and in this capacity, serves as the official IND sponsor and liaisons with the FDA with respect to all regulatory requirements. Currently, the DMID IND portfolio is comprised of approximately 75% vaccine and other biologic (monoclonal) INDs, 20% drug INDs, and 5% MFs. DMID also sponsors Investigational Device Exemption applications (IDE) and supports interaction with the FDA for studies that support 501(k) filings. The purpose of this solicitation is to provide scientific, regulatory, technical, project management, and administrative assistance for a broad spectrum of DMID research activities poised for regulatory approval or licensure. It is anticipated that a single cost-reimbursement, level of effort type contract will be awarded with a one-year base period of performance beginning on or around June 2022. It is anticipated that the contract will include six Term Option Periods, with a term of 12 months for each Term Option exercised, and the inclusion of quantity options for each contract year to be exercised at the discretion of the government. The total potential period of performance, including options, is seven years. Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about April 22, 2021, and may be accessed through beta.SAM.gov. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.

103242	<a href="#">RFA-AI-21-019 -- Radiation-Induced Immune Dysfunction (U01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-019	25-Jul-2021 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Thomas A. Winters, Ph.D.
Contact Telephone	301-761-7918
Contact Email	<a href="mailto:twinters@mail.nih.gov">twinters@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	25-Jul-2021 [Optional][LOI/Pre-App], 24-Aug-2021
Synopsis	Research funded by this initiative will examine the effects of radiation exposure on the immune system and explore possible treatments for radiation-induced immune dysfunction. Research gaps exist in understanding the mechanisms of injury and

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

repair with regard to radiation-induced immune system dysfunction, and these gaps must be addressed to better develop medical countermeasures (MCMs) for radiation exposure. Through this initiative, the NIAID Radiation and Nuclear Countermeasures Program (RNCP) will support development of animal models for immune-targeted radiation injuries, studies to better understand radiation impacts on the immune system (including immune system-mediated multi-organ injury), identification of immune-specific pathways targeted by radiation, as well as biomarkers of exposure and mitigators/treatments that target immune-related radiation response pathways.

091509	<a href="#">Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-158	28-Jul-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Jon Warren, Ph.D.
Contact Telephone	240-627-3032
Contact Email	<a href="mailto:JWarren@niaid.nih.gov">JWarren@niaid.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	28-Jul-2021 , 28-Jul-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support high risk, high impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high risk, high impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated "Go/No-Go" criteria by the end of Year 2.

103266	<a href="#">AMENDMENT -- Syphilis Specimen Collection</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	75N93021R00005	01-Jul-2021	Not Specified
--------	---	--	----------------	-------------	---------------

Contact Name	Aytaj Vily
Contact Telephone	301-761-5131
Contact Email	<a href="mailto:aytaj.vily@nih.gov">aytaj.vily@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jul-2021
Synopsis	Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Enteric and Sexually Transmitted Infections Branch (ESTIB) has a requirement for the design and performance of a longitudinal, multisite clinical study that will enroll untreated patients who have primary, secondary or early latent syphilis. Description Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS) strives to understand, treat and ultimately prevent the myriad of infectious and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control and prevent diseases caused by infectious agents. This includes basic and applied research to develop and evaluate therapeutics, vaccines, and diagnostics, which are funded through a variety of research grants and contracts. The NIAID Enteric and Sexually Transmitted Infections Branch supports research in bacterial enteric pathogens and sexually transmitted infections (STIs). Syphilis is an STI caused by the bacterial pathogen *Treponema pallidum*. The number of syphilis cases, especially congenital syphilis, has significantly increased nationally in the last five years. The CDC reported over 100,000 cases of syphilis in the U.S. in 2018, which is a 14% increase from 2017, and that year there was also a 40% rise in cases of congenital syphilis. Therefore, urgent efforts are needed to design and implement control and preventive measures for syphilis. Suboptimal syphilis diagnostics and insufficient information on the human immune response to *T. pallidum* infection pose a critical barrier to syphilis efforts. Most cases of syphilis are diagnosed by using a screening algorithm involving multiple serum antibody tests, all with imperfect specificity and sensitivity. Although these tests have been used in some fashion since the 1930s, they have well-known limitations including the inability to reliably distinguish between current and past infections, and difficulty in determining cure after antibiotic administration. In the past few decades, modern molecular techniques such as nucleic acid amplification systems and platforms, transcriptomics, proteomics and metabolomics have been developed and successfully applied to diagnosis of infectious diseases. However, developers of potential syphilis diagnostics have little to no access to high-quality syphilis patient specimens for advancing product development. This RFP is intended to fill this gap and facilitate efforts towards syphilis control, prevention and ultimately elimination. The 16-month contract Base will include protocol development, activation of multiple clinical sites, protocol implementation and the collection and delivery of specimens from a minimum of 50 patients with confirmed syphilis, or possibly have serofast status, who complete the protocol. Three 10-month Options will be for the collection of specimens from a minimum of 75 syphilis patients per option. The number and identity of participating clinical sites shall be determined by the contractor. The contractor also shall institute a panel of syphilis experts that will evaluate each patient’s clinical data and adjudicate the final diagnosis and stage of disease (primary, secondary or early latent syphilis, along with a subset of serofast patients if proposed). The contractor shall send specimens to an NIAID-supported repository from patients who have completed the study along with all metadata that includes, but is not limited to, the adjudication of the expert panel and results from all syphilis-related and other pertinent diagnostic/medical tests.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100387	<a href="#">Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)</a>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-054	20-Jun-2021 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name   Heiyoung Park, Ph.D.</p> <p>Contact Telephone   301-594-5032</p> <p>Contact Email   <a href="mailto:parkh1@mail.nih.gov">parkh1@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021 , 18-Feb-2022 [Optional][LOI/Pre-App], 18-Mar-2022 , 20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.</p>				
100388	<a href="#">Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)</a>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-055	20-Jun-2021 [Optional][LOI/Pre-App]	1,200,000 USD
	<p>Contact Name   Heiyoung Park, Ph.D.</p> <p>Contact Telephone   301-594-5032</p> <p>Contact Email   <a href="mailto:parkh1@mail.nih.gov">parkh1@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021 , 18-Feb-2022 [Optional][LOI/Pre-App], 18-Mar-2022 , 20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022</p> <p>This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.</p>			
100718	<p><a href="#">NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)</a></p>	<p>National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS</p>	<p>PAR-21-036</p>	<p>02-Jul-2021</p>	<p>Not Specified</p>
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p><a href="mailto:NIAMSclinicaltrials@mail.nih.gov">NIAMSclinicaltrials@mail.nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>02-Jul-2021 , 02-Nov-2021 , 04-Mar-2022 , 01-Jul-2022 , 04-Nov-2022 , 03-Mar-2023 , 02-Jul-2023 , 03-Nov-2023</p> <p>This Funding Opportunity Announcement (FOA) solicits cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases). Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with an R34 planning phase (Part 1) followed by an application for the U01 (Part 2). Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without an awarded R34. The NIAMS expects trials to be hypothesis-driven and have the potential for high impact within the research mission of the NIAMS.</p>			
088239	<p><a href="#">NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed</a></p>	<p>National Institute of Arthritis and Musculoskeletal and Skin</p>	<p>PAR-20-090</p>	<p>01-Jul-2021</p>	<p>300,000 USD</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Diseases/NIH/DHHS					
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>NIAMS Clinical Research Team</p> <p><a href="mailto:NIAMScinicaltrials@mail.nih.gov">NIAMScinicaltrials@mail.nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>01-Jul-2021 , 01-Nov-2021 , 01-Mar-2022 , 01-Jul-2022 , 01-Nov-2022</p> <p>This Funding Opportunity Announcement (FOA) will support planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to enable the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of an R34 planning grant or documentation that planning has been addressed is required prior to submission of an application through a NIAMS U01 clinical trial implementation application that will support the actual implementation and conduct of the study. The planning should facilitate the launching of a trial that is hypothesis-driven, milestone-defined, and has the potential for high impact within the research mission of the NIAMS.</p>			
100720	<p><a href="#">Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)</a></p>	<p>National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS</p>	<p>PAR-21-053</p>	<p>02-Jul-2021</p>	<p>475,000 USD</p>
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Yan Wang, M.D., Ph.D.</p> <p>301-594-5032</p> <p><a href="mailto:wangy1@mail.nih.gov">wangy1@mail.nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>02-Jul-2021 , 02-Nov-2021 , 04-Mar-2022 , 01-Jul-2022 , 04-Nov-2022 , 03-Mar-2023 , 02-Jul-2023 , 03-Nov-2023</p> <p>This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about disease symptoms, stages, and timing of disease progression; comorbid conditions; availability of potential research participants; and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA.

100719	<a href="#">Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)</a>	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-045	02-Jul-2021	400,000 USD
--------	--	--	------------	-------------	-------------

Contact Name	Yan Wang, M.D., Ph.D.
Contact Telephone	301-594-5032
Contact Email	<a href="mailto:wangy1@mail.nih.gov">wangy1@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	02-Jul-2021 , 02-Nov-2021 , 04-Mar-2022 , 01-Jul-2022 , 04-Nov-2022 , 03-Mar-2023 , 02-Jul-2023 , 03-Nov-2023
Synopsis	This Funding Opportunity Announcement (FOA) is designed to facilitate clinical trials that can be completed within a limited timeframe and budget. A broad range of types of exploratory studies may be submitted to this FOA. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies.

100820	<a href="#">Biological Testing Facility (X01 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-078	15-Jul-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Daniel S. Johnston, PhD
Contact Telephone	301-827-4663
Contact Email	<a href="mailto:Daniel.Johnston@nih.gov">Daniel.Johnston@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jul-2021 , 14-Jan-2022 , 15-Jul-2022
Synopsis	The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program. This FOA aims to position innovative and validated methods for future clinical

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		development. Applicants do not need to have current NIH funding to apply, but priority may be given to programs receiving NIH support at the time of application submission.			
102942	<a href="#">RFA-HD-22-006 -- Pediatric Scientist Development Program (K12 Independent Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-22-006	29-Jun-2021 [Optional][LOI/Pre-App]	7,000,000 USD
	Contact Name	Karen K. Winer			
	Contact Telephone	301-435-6877			
	Contact Email	<a href="mailto:winerk@mail.nih.gov">winerk@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021			
	Synopsis	This funding opportunity announcement (FOA) invites applications for the pediatric scientist development program (PSDP). This program constitutes a national network of mentors and scholars, in contrast to K12 programs that are based solely at a single applicant institution. The program will be responsible for identifying pediatricians who have completed their clinical training and who have promising research potential, and for matching them with established mentors with strong records of mentoring and research productivity. The program will develop guidelines for mentoring and career development in order to promote the successful transition of the candidates into independent research careers in academic settings.			
103217	<a href="#">RFA-HD-22-010 -- Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-22-010	29-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Esther Eisenberg, MD, MPH			
	Contact Telephone	301-496-6516			
	Contact Email	<a href="mailto:eisenbes@mail.nih.gov">eisenbes@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage the small business community to collaborate with scientists and clinicians in the fields of female and male reproductive medicine, infertility, andrology/urology, and			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		gynecology to develop, adapt and validate discoveries in genomics, epigenomics, metabolomics and biomarkers to the clinical diagnosis and treatment of women and men with infertility, and diseases and disorders that affect fertility. The ultimate goal is to advance the application of precision medicine to reproductive health through the development of new procedures, assays, digital apps, devices or technologies that improve the specificity, accuracy and rapidity of diagnosis and enhance the individualization, safety and convenience of clinical care.			
103524	<a href="#">RFA-HD-22-018 -- Biomarker Research to Support Fertility Regulation Development by Small Business (R43 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-22-018	29-Jun-2021 [Optional][LOI/Pre-App]	259,613 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Christopher C. Lindsey, PhD 301-435-6907 <a href="mailto:chris.lindsey@mail.nih.gov">chris.lindsey@mail.nih.gov</a>  <a href="#">Link to program URL</a> 29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021 The purpose of this Funding Opportunity Announcement (FOA) is to invite SBIR applications to support and facilitate the development of new and/or improved clinical biomarkers and companion biomarker diagnostics (e.g., point of care and/or direct-to-consumer tests, DTC) to support the clinical development of non-hormonal contraceptive product(s) for men and women.			
103573	<a href="#">RFA-HD-22-004 -- Developmental Mechanisms of Human Structural Birth Defects (P01 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-22-004	29-Jun-2021 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Reiko Toyama, PhD 301-435-2723 <a href="mailto:toyamar@mail.nih.gov">toyamar@mail.nih.gov</a>  <a href="#">Link to program URL</a> 29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021 The purpose of this funding opportunity announcement (FOA) is to support innovative, multidisciplinary, interactive, and			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

synergistic program projects that integrate basic, translational, and clinical approaches to understanding the developmental biology and genetic basis of significant congenital human malformations. Each program project will consist of three component research projects, in addition to associated cores. At least one project must use basic research in an animal model system and at least one project must be clinical or translational in nature. The component research projects must share a common central theme, focus, or objective on a specific major developmental defect or malformation that is genotypically, mechanistically, biologically, or phenotypically analogous or homologous in both animal models and humans. Any non-mammalian or mammalian animal model may be used, as long as it contributes to the common overall theme or objective of the program project. The component research projects should share a common developmental gene, process, mechanism, pathway, or phenotype.

103463	<a href="#">RFA-HD-22-014 -- Coordinating Center for the NICHD Population Dynamics Centers Research Infrastructure Program FY 2022 (R24 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-22-014	29-Jun-2021 [Optional][LOI/Pre-App]	600,000 USD
--------	---	---	---------------	--	----------------

Contact Name	Rosalind B. King, PhD
Contact Telephone	301-435-6986
Contact Email	<a href="mailto:rozking@mail.nih.gov">rozking@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021
Synopsis	The purpose of this funding announcement is to support a coordinating center for the NICHD Population Dynamics Centers Research Infrastructure Programs.

103462	<a href="#">RFA-HD-22-013 -- Population Dynamics Centers Research Infrastructure Program FY 2022 (P2C Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-22-013	29-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	---------------	--	------------------

Contact Name	Rosalind B. King, PhD
Contact Telephone	301-435-6986
Contact Email	<a href="mailto:rozking@mail.nih.gov">rozking@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.			
102397	<a href="#">RFA-DE-22-001 -- NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-22-001	08-Jun-2021 [Optional][LOI/Pre-App]	5,200,000 USD
	Contact Name	Lillian Shum, PhD			
	Contact Telephone	301-594-0618			
	Contact Email	<a href="mailto:ShumL@mail.nih.gov">ShumL@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021 , 26-Jul-2021			
	Synopsis	The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.			
080580	<a href="#">RFA-DK-19-004 -- Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-19-004	01-Jun-2021 [Optional][LOI/Pre-App]	3,750,000 USD
	Contact Name	Peter J. Perrin, Ph.D.			
	Contact Telephone	301-451-3759			
	Contact Email	<a href="mailto:Peter.Perrin@nih.gov">Peter.Perrin@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2021 [Optional][LOI/Pre-App], 01-Jul-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.</p>			
102917	<a href="#">RFA-DK-20-034 -- Program to Advance the Career Development of Scientists from Diverse Backgrounds Conducting Nutrition, Obesity, Diabetes, and Related Research (U24 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-034	14-Jun-2021 [Optional][LOI/Pre-App]	2,650,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Mary E. Evans, Ph.D.</p> <p>301-594-4578</p> <p><a href="mailto:evansmary@niddk.nih.gov">evansmary@niddk.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021</p> <p>The purpose of this Funding Opportunity Announcement is to enhance the diversity of the research workforce who are available to successfully compete for independent research funding from NIH in the areas of nutrition, obesity, diabetes, and related conditions. This program will establish a consortium providing professional development, mentoring, networking, pilot and feasibility funds, and other opportunities designed to advance the career development of post-doctoral scholars and early career faculty from diverse backgrounds, including those from groups nationally underrepresented in biomedical and behavioral research, who intend to pursue a research career focused on nutrition, obesity, diabetes, and/or related conditions. The program will be administered through research institutions with substantial existing NIH funding within the research mission of NIDDK.</p>			
103291	<a href="#">RFA-DK-21-501 -- Limited Competition: Revision to the Longitudinal Monitoring of Pancreas Architecture in the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-21-501	17-Jul-2021 [Optional][LOI/Pre-App]	4,500,000 USD
	<p>Contact Name</p>	<p>Aynur Unalp-Arida, MD, MSc, PhD</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-594-8879</p> <p>Contact Email   <a href="mailto:aynur.unalp-arida@nih.gov">aynur.unalp-arida@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   17-Jul-2021 [Optional][LOI/Pre-App], 17-Aug-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites one application from the Program Director/Principal Investigator (PD/PI) of the current Data Coordinating Center (DCC) for Type 1 Diabetes Acute Pancreatitis Consortium (T1DAPC). This 5-year longitudinal observational clinical study was originally funded in September 2020 and is currently in its planning phase. It will conduct a prospective longitudinal observational study of the occurrence of new onset diabetes during an acute pancreatitis (AP) episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study is designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes after AP. The DCC is involved in coordination and study design, including data and biosample acquisition and management and is responsible for distribution of funding to the clinical centers for participant costs. This FOA provides funding for the T1DAPC DCC to support longitudinal Magnetic Resonance Imaging (MRI) and other types of biomarker studies of enrolled participants.</p>				
083080	<p><a href="#">Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)</a></p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-294	14-Jul-2021	Not Specified
	<p>Contact Name   Aaron C. Pawlyk, Ph.D.</p> <p>Contact Telephone   301-451-7299</p> <p>Contact Email   <a href="mailto:pawlykac@mail.nih.gov">pawlykac@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Jul-2021 , 12-Nov-2021</p> <p>Synopsis   The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, and hematology. Additional information concerning programmatic areas at NIDDK is available at <a href="http://www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx">www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx</a> and applicants are strongly encouraged to discuss research priorities with the Scientific Contact. The objective of this FOA is to stimulate early-stage preclinical</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>validation of therapeutic leads (that need not be finalized therapeutics, henceforth called "therapeutic leads") such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies. This must be articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, generating lists of putative new targets, or identifying new therapeutic uses for existing compounds. At the end of the project period, a successful project will have provided a significant contribution to the data supporting the validity around a therapeutic such that it can advance further through other funding mechanisms, such as the small business program (<a href="https://sbir.nih.gov/niddk/index">https://sbir.nih.gov/niddk/index</a>).</p>			
076166	<a href="#">Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-854	11-Jun-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Mary Evans, Ph.D.</p> <p>301-594-4578</p> <p><a href="mailto:evansmary@mail.nih.gov">evansmary@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>11-Jun-2021 , 09-Jul-2021 , 10-Aug-2021 , 10-Sep-2021</p>			
	Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism.</p>			
084593	<a href="#">RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-19-011	01-Jun-2021	275,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Martha I. Barnes, MS</p> <p>Contact Telephone   919-541-3335</p> <p>Contact Email   <a href="mailto:barnes@niehs.nih.gov">barnes@niehs.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jun-2021 , 01-Jul-2021 , 02-Aug-2021 , 01-Sep-2021 , 01-Oct-2021 , 01-Nov-2021 , 01-Dec-2021 , 03-Jan-2022 , 01-Feb-2022 , 01-Mar-2022 , 01-Apr-2022 , 02-May-2022 , 01-Jun-2022 , 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022</p> <p>Synopsis   This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.</p>				
104078	<a href="#">RFA-ES-21-005 -- SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-21-005	30-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Kathy Ahlmark</p> <p>Contact Telephone   984-287-3231</p> <p>Contact Email   <a href="mailto:ahlmark@niehs.nih.gov">ahlmark@niehs.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to further the development of Advanced Technology Training (ATT) products for: the health and safety training of hazardous materials (HAZMAT) workers; waste treatment personnel; skilled support personnel associated with an emergency/disaster; emergency responders in biosafety response, infectious disease training and cleanup; emergency responders in disasters and resiliency training; and for ATT tools to assist in responding to</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>environmental disasters. ATT as defined by the Worker Training Program (WTP) includes, but is not limited to, online training, mobile device training, virtual reality, and serious gaming, which complement all aspects of training from development to evaluation including advanced technologies that enhance, supplement, improve, and provide health and safety training for hazardous materials workers. These products must complement the goals and objectives of WTP. The major objective of the NIEHS WTP is to prevent work related harm by assisting in the training of workers in how best to protect themselves and their communities from exposure to hazardous materials. The financial support for this initiative comes directly from NIEHS Worker Education and Training Branch SBIR funds.</p>			
091401	<a href="#">NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)</a>	National Institute of General Medical Sciences/NIH/DHHS	PAR-20-153	13-Jul-2021	1,250,000 USD
	Contact Name	Tony Beck, Ph.D.			
	Contact Telephone	301-480-4623			
	Contact Email	<a href="mailto:beckl@mail.nih.gov">beckl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Jul-2021 , 13-Jul-2022			
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities Curriculum or Methods Development Outreach Information on current SEPA projects can be found at: <a href="https://www.nigms.nih.gov/Research/crcb/sepa/Pages/default.aspx">https://www.nigms.nih.gov/Research/crcb/sepa/Pages/default.aspx</a> and <a href="https://www.nihsepa.org">https://www.nihsepa.org</a> Applicants are strongly encouraged to consult with the SEPA Scientific/Research Contact to be advised on the appropriateness of the intended project for SEPA program objectives and the priorities of the NIGMS.</p>			
087255	<a href="#">RFA-MH-20-506 -- Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-506	01-Jun-2021 [Optional][LOI/Pre-App]	450,000 USD
	Contact Name	Matthew Rudorfer, M.D.			
	Contact Telephone	301-443-1111			
	Contact Email	<a href="mailto:mrudorfe@mail.nih.gov">mrudorfe@mail.nih.gov</a>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 [Optional][LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage practice-based research aimed at refining and pilot testing developmentally-focused, theory-based efficacious prevention interventions that may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities. This FOA is published in parallel to a companion FOA ( RFA-MH-20-505 ) that uses the R01 funding mechanism to support larger-scale, fully powered trials with this focus.</p>				
087253	<a href="#">RFA-MH-20-505 -- Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-505	01-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Matthew Rudorfer, M.D.</p> <p>Contact Telephone 301-443-1111</p> <p>Contact Email <a href="mailto:mrudorfe@mail.nih.gov">mrudorfe@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 [Optional][LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage practice-based research aimed at testing the effectiveness of developmentally-focused theory-based efficacious prevention interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities. This FOA seeks to support clinical trials to establish the effectiveness of scalable prevention interventions when implemented using available resources within pediatric-serving primary care settings. This FOA is published in parallel to a companion R34 FOA (RFA-MH-20-506) that supports pilot effectiveness studies in preparation for the larger-scale, fully powered studies described in this FOA.</p>				
100022	<a href="#">RFA-MH-20-620 -- BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-620	10-Jul-2021 [Optional][LOI/Pre-App]	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Ashlee Van't Veer, PhD</p> <p>Contact Telephone   301-443-3107</p> <p>Contact Email   <a href="mailto:Brain.Initiative.Training@nih.gov">Brain.Initiative.Training@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   10-Jul-2021 [Optional][LOI/Pre-App], 10-Aug-2021 , 11-Mar-2022 [Optional][LOI/Pre-App], 11-Apr-2022 , 09-Nov-2022 [Optional][LOI/Pre-App], 09-Dec-2022</p> <p>Synopsis   The purpose of the The Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
087256	<a href="#">RFA-MH-20-510 -- Laboratories to Optimize Digital Health (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-510	01-Jul-2021	Not Specified
	<p>Contact Name   Adam Haim, Ph.D.</p> <p>Contact Telephone   301-435-3593</p> <p>Contact Email   <a href="mailto:Haima@mail.nih.gov">Haima@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jul-2021 , 01-Mar-2022</p> <p>Synopsis   NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical trials testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness.
103575	<a href="#">RFA-MH-21-230 -- Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-230	01-Jun-2021 [Optional][LOI/Pre-App]	450,000 USD
	Contact Name	Mary Rooney, Ph.D.			
	Contact Telephone	301-827-1325			
	Contact Email	<a href="mailto:mary.rooney@nih.gov">mary.rooney@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2021 [Optional][LOI/Pre-App], 01-Jul-2021 , 30-Jan-2022 [Optional][LOI/Pre-App], 01-Mar-2022			
	Synopsis	NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of interventions targeting preschool attention deficit hyperactivity disorder (ADHD) symptoms and impairments. An emphasis is placed on studies that take a theory-driven, empirical approach to developing and testing interventions intended to impact current ADHD symptoms and impairments and/or prevent or forestall the emergence of co-occurring disorders or additional ADHD-related impairments. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach, to address whether the intervention engages the target mechanisms presumed to underlie the intervention effects, and to obtain preliminary data needed to inform a larger, more definitive test of the intervention.			
103821	<a href="#">RFA-NS-21-022 -- Translational Neural Devices (U44 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-21-022	01-Jul-2021	Not Specified
	Contact Name	Nick Langhals, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	<a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jul-2021 , 20-Oct-2021 , 18-Feb-2022 , 20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 19-Jun-2023 , 18-Oct-2023 , 20-Feb-2024			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.</p>			
103817	<a href="#">RFA-NS-21-021 -- Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-21-021	01-Jul-2021	Not Specified
	Contact Name	Nick Langhals, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	<a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jul-2021 , 20-Oct-2021 , 18-Feb-2022 , 20-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 19-Jun-2023 , 18-Oct-2023 , 20-Feb-2024			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.</p>			
104038	<a href="#">RFA-NS-21-020 -- Research Program Award (R35 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-21-020	13-Jun-2021 [Optional][LOI/Pre-	6,000,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

App]

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Alisa Schaefer, Ph.D.</p> <p>301-496-9248</p> <p><a href="mailto:alisa.schaefer@nih.gov">alisa.schaefer@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>13-Jun-2021 [Optional][LOI/Pre-App], 13-Jul-2021</p> <p>The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support, and increased freedom and flexibility, to Program Directors (PDs)/Principal Investigators (PIs), to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II). This greater funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; More time for PDs/PIs to mentor and foster a diverse workforce in their laboratories. The RPA is a signature program for NINDS, as such NINDS strives to ensure it reflects our commitment to enhancing the diversity and inclusiveness of the neuroscience workforce. A diverse NIH-supported scientific workforce, including individuals from underrepresented groups, fosters scientific innovation, enhances global competitiveness, contributes to robust learning environments, and improves the quality of the research. Notice of NIH's Interest in Diversity. NINDS will work to ensure that it maintains a broad and diverse research portfolio in terms of scientific areas, approaches, regions, institutions, and individuals. Such diversity will optimize returns on the Institute's investments by maximizing the ideas explored and the chances for important breakthroughs. Note that, while this funding opportunity also accepts clinical trials, only applications proposing "mechanistic clinical trials or studies" or basic experimental studies with humans (BESH) will be accepted. For information on the types of clinical trial that are within scope of this funding opportunity announcement, refer to Funding Opportunity Description, below.</p>
---	---

081489	<a href="#">Limited Competition: Modular Budget Research Project Grant</a>	National Institute of Nursing	PAR-19-256	06-Jul-2021	1,250,000
--------	--	-------------------------------	------------	-------------	-----------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">for NIH Nurse Scientist Scholars (R01 Clinical Trial Optional)</a>	Research/NIH/DHHS			USD
	<p>Contact Name   David Banks, PhD, MPH, RN</p> <p>Contact Telephone   301-496-9558</p> <p>Contact Email   <a href="mailto:david.banks@nih.gov">david.banks@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   06-Jul-2021 , 04-Oct-2021 , 06-Jul-2022</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to encourage modular budget R01 grant applications from nurse scientists who are currently or were supported within the last 3 years by an NIH Career Development (K) award. This opportunity is limited to those K awardee nurse scientists who have NIH New Investigator status. Through this opportunity, NINR seeks to enhance the transition of nurse scientists to independent investigator status.</p>				
085884	<a href="#">Patient Activation for Self-Management of Chronic Conditions (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-382	16-Jun-2021	400,000 USD
	<p>Contact Name   Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone   301-594-5970</p> <p>Contact Email   <a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2021 , 16-Jul-2021 , 07-Sep-2021 , 16-Feb-2022 , 16-Mar-2022 , 07-May-2022 , 16-Jun-2022 , 16-Jul-2022 , 07-Sep-2022 , 16-Feb-2023 , 16-Mar-2023 , 07-May-2023</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.</p>				
085882	<a href="#">Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-381	05-Jun-2021	Not Specified
	<p>Contact Name   Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone   301-594-5970</p> <p>Contact Email   <a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2021 , 05-Jul-2021 , 07-Sep-2021 , 05-Feb-2022 , 05-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Feb-2023 , 05-Mar-2023 , 07-May-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.			
097721	<a href="#">Notice of Special Interest (NOSI): Sex and Gender Differences in Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD)</a>	National Institute on Aging/NIH/DHHS	NOT-AG-20-038	09-Jul-2021	Not Specified
	Contact Name	Amelia Karraker, Ph.D.			
	Contact Telephone	301-496-3131			
	Contact Email	<a href="mailto:amelia.karraker@nih.gov">amelia.karraker@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Jul-2021 , 12-Nov-2021			
	Synopsis	This Notice of Special Interest (NOSI) is intended to promote multidisciplinary research to clarify sex and gender differences in the risk, development, progression, diagnosis, and clinical presentation of Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD). Studies that examine sex and gender differences in outcomes (e.g., clinical, functional, well-being) among people living with AD/ADRD are also relevant. Broad areas of interest include biological (e.g., hormonal, genetic, metabolic, comorbidity-related), neuroscientific (e.g., neural systems and functions), behavioral (e.g., physical activity, substance use, social engagement), social (e.g., history of maltreatment or adversity, child rearing, marital status, education, employment), psychological (e.g., depression, cognitive ability, emotional function, stress reactivity, personality), and healthcare profession (e.g., provider knowledge and attitudes about dementia) and healthcare system-level (e.g., access to care) factors and processes that separately or together may drive observed differences by sex and gender and/or may operate differently by sex and gender. Studies that account for methodological and measurement issues that may drive sex and gender differences are also of interest.			
101208	<a href="#">Notice of Special Interest (NOSI): Sensory and Motor System Changes as Predictors of Preclinical Alzheimer's Disease</a>	National Institute on Aging/NIH/DHHS	NOT-AG-20-053	09-Jul-2021	Not Specified
	Contact Name	Coryse St. Hillaire-Clarke, Ph.D.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-827-6944</p> <p>Contact Email   <a href="mailto:sthillaireclacn@mail.nih.gov">sthillaireclacn@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   09-Jul-2021 , 12-Nov-2021</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to encourage applications that propose either basic, clinical, or a combination of basic and clinical studies to investigate how functional changes in the sensory and/or motor systems impact the development and progression of Alzheimer's disease. Studies may include older adults and/or animal models and may employ a variety of approaches, including but not limited to cellular, molecular, imaging, physiological, and genetic, to address this need. For clinical studies, leveraging of existing longitudinal cohorts already collecting sensory and motor assessments is highly encouraged.</p>				
078596	<a href="#">Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-19-071	09-Jul-2021	275,000 USD
	<p>Contact Name   Robin A. Barr, D.Phil.</p> <p>Contact Telephone   301-402-7715</p> <p>Contact Email   <a href="mailto:BarrR@mail.nih.gov">BarrR@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   09-Jul-2021 , 12-Nov-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease and its related dementias and which need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA.</p>				
102047	<a href="#">RFA-AA-21-003 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-003	17-Jul-2021 [Optional][LOI/Pre-App]	100,000 USD
	<p>Contact Name   M. Kathy Jung. Ph.D.</p> <p>Contact Telephone   301-443-8744</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:jungma@mail.nih.gov">jungma@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 17-Jul-2021 [Optional][LOI/Pre-App], 17-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This FOA uses the R03 mechanism, which is intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.</p>				
102041	<a href="#">RFA-AA-21-004 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-004	17-Jul-2021 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name M. Kathy Jung. Ph.D.</p> <p>Contact Telephone 301-443-8744</p> <p>Contact Email <a href="mailto:jungma@mail.nih.gov">jungma@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 17-Jul-2021 [Optional][LOI/Pre-App], 17-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

considered. This FOA uses the R21 grant mechanism, which is intended to support investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research.

102040	<a href="#">RFA-AA-21-002 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-002	17-Jul-2021 [Optional][LOI/Pre-App]	750,000 USD
--------	--	---	---------------	--	-------------

Contact Name | M. Kathy Jung, Ph.D.  
 Contact Telephone | 301-443-8744  
 Contact Email | [jungma@mail.nih.gov](mailto:jungma@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 17-Jul-2021 [Optional][LOI/Pre-App], 17-Aug-2021

Synopsis | This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. Applications to this RFA should be accomplished within a three year project duration .

094254	<a href="#">RFA-DA-21-019 --Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21-019	20-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	---------------	--	---------------

Contact Name | John Satterlee, Ph.D.  
 Contact Telephone | 301-435-1020  
 Contact Email | [satterleej@nida.nih.gov](mailto:satterleej@nida.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021			
	Synopsis	The purpose of this FOA is to support generation of single cell RNA-sequencing data sets for at least one brain region relevant to persistent HIV infection and opioid, cocaine and/or methamphetamine use disorder.			
101328	<a href="#">NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-21-092	26-Jul-2021	5,000,000 USD
	Contact Name	Ivan D. Montoya, M.D., M.P.H.			
	Contact Telephone	301-827-5936			
	Contact Email	<a href="mailto:imontoya@mail.nih.gov">imontoya@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	26-Jul-2021 , 25-Jul-2022 , 25-Jul-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 will support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 will provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are encouraged to apply.			
080458	<a href="#">Behavioral &amp; Integrative Treatment Development Program (R34 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-213	23-Jul-2021	450,000 USD
	Contact Name	Will M. Aklin, Ph.D.			
	Contact Telephone	301-827-5909			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:aklinwm@mail.nih.gov">aklinwm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 23-Jul-2021 , 23-Mar-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage I research, including: (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain.</p>				
091073	<a href="#">Exploiting In Vivo or In Situ Imaging Approaches to Understand HIV-Relevant Processes in the Context of Substance Use Disorders (R61/R33 Clinical Trials Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21-005	13-Jul-2021 [Optional][LOI/Pre-App]	2,050,000 USD
	<p>Contact Name Vasundhara Varthakavi, DVM, PhD</p> <p>Contact Telephone 301-443-2146</p> <p>Contact Email <a href="mailto:vasundhara.varthakavi@nih.gov">vasundhara.varthakavi@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Jul-2021 [Optional][LOI/Pre-App], 13-Aug-2021</p> <p>Synopsis The purpose of this initiative is to support projects that further develop or exploit advances using in situ or in vivo imaging or related technologies to investigate HIV/SIV infection, latent reservoirs, the pathogenic consequences of HIV/SIV infection, or the effects of substance use, substance use disorders (SUDs), or HIV or SUD therapies on these processes. Applicants may propose primate or human studies to investigate blood, lymphoid, or brain tissues.</p>				
080453	<a href="#">Behavioral &amp; Integrative Treatment Development Program (R01 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-212	23-Jul-2021	Not Specified
	Contact Name Will M. Aklin, Ph.D.				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-827-5909</p> <p>Contact Email   <a href="mailto:aklinwm@mail.nih.gov">aklinwm@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   23-Jul-2021 , 23-Mar-2022</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage II and Stage III efficacy research, including: (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain</p>				
103798	<a href="#">RFA-DA-22-001 -- Mobile Health Solutions to Rectify Digital Inequality in Communities Affected by Drug Addiction (R43/R44 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-001	13-Jul-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Leonardo Angelone, PhD</p> <p>Contact Telephone   301-827-5946</p> <p>Contact Email   <a href="mailto:leonardo.angelone@nih.gov">leonardo.angelone@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   13-Jul-2021 [Optional][LOI/Pre-App], 13-Aug-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA), issued by the National Institute on Drug Abuse (NIDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications to develop mobile health technologies, including wearables and other digital health enabled technologies, to address existing digital inequalities affecting underserved and vulnerable populations suffering from Substance Use Disorders (SUD).</p>				
086925	<a href="#">Building Population Health Research Capacity in the U.S. Affiliated Pacific Islands (U24 – Clinical Trial Not Allowed)</a>	National Institute on Minority Health and Health	PAR-20-048	15-Jul-2021	2,000,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Disparities/NIH/DHHS					
	<p>Contact Name   Jennifer Alvidrez, PhD</p> <p>Contact Telephone   301-594-9567</p> <p>Contact Email   <a href="mailto:alvidrezjl@mail.nih.gov">alvidrezjl@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jul-2021 , 15-Jul-2022</p> <p>Synopsis   The purpose of this initiative is to build the capacity of organizations in the US-Affiliated Pacific Islands to conduct ongoing population health research in this region.</p>				
081503	<a href="#">Limited Competition: Modular Budget Research Project Grant for NIH Nurse Scientist Scholars (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-19-256	06-Jul-2021	1,250,000 USD
	<p>Contact Name   David Banks, PhD, MPH, RN</p> <p>Contact Telephone   301-496-9558</p> <p>Contact Email   <a href="mailto:david.banks@nih.gov">david.banks@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   06-Jul-2021 , 04-Oct-2021 , 06-Jul-2022</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to encourage modular budget R01 grant applications from nurse scientists who are currently or were supported within the last 3 years by an NIH Career Development (K) award. This opportunity is limited to those K awardee nurse scientists who have NIH New Investigator status. Through this opportunity, NINR seeks to enhance the transition of nurse scientists to independent investigator status.</p>				
100768	<a href="#">Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-023	19-Jul-2021	2,500,000 USD
	<p>Contact Name   Lori Ducharme, Ph.D.</p> <p>Contact Telephone   301-827-6331</p> <p>Contact Email   <a href="mailto:Lori.Ducharme@nih.gov">Lori.Ducharme@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 19-Jul-2021 , 15-Nov-2021 , 19-Jul-2022 , 15-Nov-2022 , 19-Jul-2023 , 15-Nov-2023</p> <p>Synopsis The purpose of this FOA is to support the development, adaptation, and pilot testing of implementation strategies to achieve system-level adoption of evidence-based interventions, guidelines, or practices to improve the delivery, quality, and sustainability of prevention or treatment services for substance use disorders.</p>				
100767	<a href="#">Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-022	19-Jul-2021	2,500,000 USD
	<p>Contact Name Lori Ducharme, Ph.D.</p> <p>Contact Telephone 301-827-6331</p> <p>Contact Email <a href="mailto:Lori.Ducharme@nih.gov">Lori.Ducharme@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 19-Jul-2021 , 15-Nov-2021 , 19-Jul-2022 , 15-Nov-2022 , 19-Jul-2023 , 15-Nov-2023</p> <p>Synopsis The purpose of this FOA is to support the development and testing of implementation strategies to achieve system-level adoption of evidence-based interventions, guidelines, or practices to improve the delivery, quality, and sustainability of prevention or treatment services for substance use disorders.</p>				
075927	<a href="#">Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-18-843	16-Jul-2021	275,000 USD
	<p>Contact Name Daniel Gilchrist, Ph.D.</p> <p>Contact Telephone 301-496-7531</p> <p>Contact Email <a href="mailto:daniel.gilchrist@nih.gov">daniel.gilchrist@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jul-2021 , 07-Sep-2021</p> <p>Synopsis National Human Genome Research Institute (NHGRI) invites applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address larger and larger data sets. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>			
102271	<a href="#">RFA-OD-21-002 -- Tobacco Regulatory Science (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-OD-21-002	15-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Rachel Grana Mayne, PhD</p> <p>240-276-5899</p> <p><a href="mailto:granar@nih.gov">granar@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>15-May-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 17-Dec-2021 [Optional][LOI/Pre-App], 15-Feb-2022 , 15-May-2022 [Optional][LOI/Pre-App], 14-Jul-2022 , 17-Dec-2022 [Optional][LOI/Pre-App], 14-Feb-2023</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.</p>			
097523	<a href="#">RFA-HG-20-048 -- Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-HG-20-048	08-Jun-2021 [Optional][LOI/Pre-App]	2,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Nicole Lockhart</p> <p>301-385-1622</p> <p><a href="mailto:lockhani@mail.nih.gov">lockhani@mail.nih.gov</a></p>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021</p> <p>Synopsis The purpose of this initiative is to support investigator-initiated research on genetic counseling processes and practices in genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Applications will assess, innovate, scale, and/or research the implementation of novel genetic counseling practices to address the need for more healthcare professionals trained in genetic counseling; the uneven access to in-person genetic counseling across U.S. health care systems; and the challenges of effective and efficient communication of genomic findings to clinicians, patients, and families.</p>				
097805	<a href="#">RFA-MH-20-600 -- BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-MH-20-600	14-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Ming Zhan, Ph.D.</p> <p>Contact Telephone 301-827-3678</p> <p>Contact Email <a href="mailto:ming.zhan@nih.gov">ming.zhan@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 14-Jun-2022 [Optional][LOI/Pre-App], 14-Jul-2022 , 14-Jun-2023 [Optional][LOI/Pre-App], 14-Jul-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the research community to incorporate tools that allow users to analyze and visualize the data, but the creation of such tools is not part of this FOA. The data archives will use appropriate standards to describe the data, but the creation of such standards is not part of this FOA. A goal of this program is to advance research by creating a community resource data archive with appropriate standards and summary information that is broadly available and accessible to the research community for furthering research.</p>				
102912	<a href="#">Research on Bat Immunology (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-184	15-Jul-2021	275,000 USD
	<p>Contact Name Kentner Singleton, Ph.D.</p> <p>Contact Telephone 240-669-5499</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:singletonkl@niaid.nih.gov">singletonkl@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021 , 15-Mar-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support research to characterize cellular and molecular constituents of the bat immune system and to understand protective innate and adaptive immune mechanisms in bats.</p>				
102922	<p><a href="#">Notice of Special Interest (NOSI): Administrative Supplements for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project</a></p>	National Institutes of Health/DHHS	NOT-OD-20-024	12-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 23-Jul-2021 , 23-Nov-2021 , 23-Mar-2022 , 23-Jul-2022</p> <p>Synopsis The Office of the Director of the National Institutes of Health (NIH) announces the opportunity for investigators with relevant active NIH-supported grants from the participating Institutes listed above to submit administrative supplement applications for funded projects to meet new NIH Down syndrome research objectives related to the NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project. This Notice is soliciting administrative supplements for the following mechanisms ONLY: R01,R03,R21,R24,P01,P20, P30,P40,P50,P51,U01,U10,U19,U24,U42,U54,UG1,UG3,UL1,U2C,K12, and T32.</p>				
096383	<p><a href="#">Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project</a></p>	National Institutes of Health/DHHS	NOT-OD-20-129	12-Jul-2021	1,000,000 USD
	<p>Contact Name Ryan Talesnik</p> <p>Contact Telephone 301-435-6976</p> <p>Contact Email <a href="mailto:talesnikr@mail.nih.gov">talesnikr@mail.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jul-2021</p> <p>Synopsis NIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. Because many people with Down syndrome are at increased risk of having co-occurring medical conditions, such as pulmonary disease, cardiac problems, obesity, diabetes, sleep apnea, and altered immune function that may predispose them to more severe infection with SARS-CoV-2, they may be particularly vulnerable to COVID-19 complications. Combined with shared living situations, and reduced access to testing and treatment services due to disparities in provision of resources, the impact of COVID-19 infection in people with Down syndrome is likely to be elevated. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.</p>				
086488	<p><a href="#">Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PAR-20-035	19-Jul-2021	2,100,000 USD
	<p>Contact Name Shelley Su, Ph.D.</p> <p>Contact Telephone 301-402-3869</p> <p>Contact Email <a href="mailto:shelley.su@nih.gov">shelley.su@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 19-Jul-2021 , 17-Nov-2021 , 17-Mar-2022 , 19-Jul-2022 , 07-Nov-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with an Exploratory/Developmental Phased Award (R61/R33) mechanism, where polysubstance research can occur in any of these</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		translational stages during the R61 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, permitting accelerated bi-directional research exchange.			
103124	<a href="#">RFA-AI-21-025 -- Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-AI-21-025	30-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Dale Burwen, MD, MPH			
	Contact Telephone	240-669-2867			
	Contact Email	<a href="mailto:dale.burwen@nih.gov">dale.burwen@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support projects to improve use of evidence-based HIV prevention interventions among populations in priority areas identified as highly impacted by HIV. Research funded under this FOA will support the goals of the DIAGNOSE and PREVENT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative towards reducing HIV incidence. Creative, multidisciplinary approaches are needed to meet the needs of specific populations and localities.			
103118	<a href="#">RFA-AI-21-024 -- Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-AI-21-024	05-Jul-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Tia Morton, R.N., M.S.			
	Contact Telephone	301-222-7795			
	Contact Email	<a href="mailto:frazierti@mail.nih.gov">frazierti@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jul-2021 [Optional][LOI/Pre-App], 04-Aug-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to utilize implementation science to develop, implement, and evaluate creative, multidisciplinary approaches to healthcare delivery that more effectively engage and retain individuals in HIV care and treatment so that they achieve durable viral suppression. Research funded under this FOA will support the			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

goals of the DIAGNOSE and TREAT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative by seeking to achieve more rapid and sustained viral suppression and improved outcomes for people with HIV through better healthcare engagement.

103117	<a href="#">RFA-AI-21-023 -- Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-AI-21-023	30-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Rosemary McKaig, PhD
Contact Telephone	240-627-3214
Contact Email	<a href="mailto:rmckaig@niaid.nih.gov">rmckaig@niaid.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support applications that address the RESPOND pillar of the Ending the HIV Epidemic: A Plan for America (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.

103216	<a href="#">RFA-AR-21-016 -- Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-AR-21-016	15-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Ricardo Cibotti, Ph.D.
Contact Telephone	301-451-5888
Contact Email	<a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jun-2021 [Optional][LOI/Pre-App], 15-Jul-2021
Synopsis	The purpose of this FOA is to establish Technology and Analytic Cores (TACs) and a Research Management Unit (RMU) for the

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) Program. The TACs include the Technology Cores and the specialized Tissue Repository and Systems Biology Cores. The goal of the AMP AIM Program is to gain a comprehensive understanding of cellular and molecular disease pathways and to identify novel targets for intervention. TACs will work together to test, optimize and apply state-of-the-art and next-generation high-dimensional, high-resolution technologies to interrogate and analyze human biopsy tissue and biosamples from patients with rheumatoid arthritis, lupus, psoriatic spectrum disease and Sjögren’s syndrome. The RMU will provide centralized management and operational support to the network including clinical monitoring for the entire AMP AIM program. All Cores and the RMU will work collaboratively with the Disease Teams (RFA-AR-21-015) to identify molecular and cellular pathways of disease by probing the structural, functional and molecular complexities of end organ tissue involvement in relevant patient populations.

103215	<a href="#">RFA-AR-21-015 -- Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjögren’s Syndrome (UC2 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-AR-21-015	15-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Ricardo Cibotti, Ph.D.
Contact Telephone	301-451-5888
Contact Email	<a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jun-2021 [Optional][LOI/Pre-App], 15-Jul-2021
Synopsis	<p>The purpose of this FOA is to establish Disease Teams for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) Program. Disease Teams (DTs) will focus on one of the following diseases: rheumatoid arthritis, lupus, psoriatic spectrum disease, or Sjögren’s syndrome. The goal of the AMP AIM Program is to gain a comprehensive understanding of cellular and molecular disease pathways and to identify novel targets for intervention. Disease Teams will lead the research efforts to define the most significant scientific opportunities that can be addressed with state of the art and next-generation tissue interrogation technologies in the context of disease de- and reconstruction approaches of AMP AIM. DTs will work collaboratively to identify molecular and cellular pathways of disease by probing the structural, functional and molecular complexities of end organ tissue in relevant patient populations with state-of the art and next generation analytics provided by the Technical and Analytic Cores (RFA-AR-21-016). DTs will work to harmonize, integrate and optimize all aspects of the data generation pipeline, from tissue collection to data analysis and interpretation.</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

103485	<a href="#">RFA-OD-21-008 -- Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-OD-21-008	07-Jul-2021	1,500,000 USD
--------	---	------------------------------------	---------------	-------------	---------------

	Contact Name	Judith A. Arroyo, PhD
	Contact Telephone	301-402-0717
	Contact Email	<a href="mailto:jarroyo@mail.nih.gov">jarroyo@mail.nih.gov</a>
	Sponsor Website	
	Program URL	<a href="#">Link to program URL</a>
	Deadline Dates (ALL)	07-Jul-2021
	Synopsis	This funding opportunity announcement (FOA) uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this initiative is provided from the American Rescue Plan Act of 2021 .

103464	<a href="#">RFA-OD-21-009 -- Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	RFA-OD-21-009	07-Jul-2021	800,000 USD
--------	---	------------------------------------	---------------	-------------	-------------

	Contact Name	Carol Blaisdell
	Contact Telephone	301-435-5606
	Contact Email	<a href="mailto:carol.blaisdell@nih.gov">carol.blaisdell@nih.gov</a>
	Sponsor Website	
	Program URL	<a href="#">Link to program URL</a>
	Deadline Dates (ALL)	07-Jul-2021
	Synopsis	High rates and disparities of COVID-19 infection, morbidity, and mortality continue among underserved and vulnerable populations across the United States. The overarching goal of the Rapid Acceleration of Diagnostics for Underserved

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Populations (RADx-UP) initiative is to understand and ameliorate factors that have placed a disproportionate burden of the pandemic on underserved and/or vulnerable populations, specifically by implementing programs that expand the scope and reach of COVID-19 testing interventions to reduce these disparities. To address barriers to testing and vaccination, social, ethical, and behavioral research is urgently needed to inform related mitigation efforts. This Phase II RADx-UP Funding Opportunity Announcement (FOA) is designed to expand research to understand and address the social, ethical, and behavioral implications (SEBI) of COVID-19 testing interventions among underserved and vulnerable populations. Desirable studies for Phase II will move beyond descriptive health disparities research to focus on developing interventions and other actionable solutions in collaboration with community partners and stakeholders. The funding for this initiative is provided from the American Rescue Plan Act of 2021.</p>			
103572	<a href="#">NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-209	27-Jul-2021	400,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Shardell Spriggs, Ph.D.</p> <p>301-443-8189</p> <p><a href="mailto:shardell.spriggs@nih.gov">shardell.spriggs@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>27-Jul-2021</p>			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to recruit Early Stage Investigators (ESI) to pursue research programs of interest to NIH Chemical Countermeasures Research Program (CCRP) under the NIH Countermeasures Against Chemical Threats (CounterACT) grant/cooperative agreement program. ESI CounterACT R21 projects may be exploratory, applied, proof of principle, or high risk-high impact research to discover safe and effective therapeutics to mitigate toxicities resulting from exposures to highly toxic chemicals. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including preliminary data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review. Projects supported by this FOA will have an extended level of support (3 years) and are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive funding support from the NIH CounterACT programs or other related initiatives. Investigators that compete successfully for this R21 mechanism will not lose their ESI status.</p>			
102986	<a href="#">RFA-MD-21-004 -- Understanding and Addressing the Impact of Structural</a>	National Institutes of	RFA-MD-21-004	20-Jul-2021	2,500,000



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)</a>	Health/DHHS		[Optional][LOI/Pre-App]	USD
	<p>Contact Name Jennifer Alvidrez, PhD</p> <p>Contact Telephone 301-594-9567</p> <p>Contact Email <a href="mailto:jennifer.alvidrez@nih.gov">jennifer.alvidrez@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jul-2021 [Optional][LOI/Pre-App], 24-Aug-2021</p> <p>Synopsis This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.</p>				
075924	<a href="#">Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-18-844	16-Jul-2021	Not Specified
	<p>Contact Name Daniel Gilchrist, Ph.D.</p> <p>Contact Telephone 301-496-7531</p> <p>Contact Email <a href="mailto:daniel.gilchrist@nih.gov">daniel.gilchrist@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jul-2021 , 07-Sep-2021</p> <p>Synopsis National Human Genome Research Institute (NHGRI) invites applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address larger and larger data sets. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
103354	<a href="#">RFA-AI-21-013 -- Understanding HIV Reservoir Dynamics (P01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-AI-21-013	30-Jun-2021 [Optional][LOI/Pre-App]	5,000,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Leia Novak, Ph.D.</p> <p>Contact Telephone   301- 761-7825</p> <p>Contact Email   <a href="mailto:Leia.novak@nih.gov">Leia.novak@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, Program Project applications aimed at understanding changes in the HIV reservoir over time in different cell types and tissues. A better understanding of the mechanisms that govern HIV reservoir dynamics over time is essential to inform the development of strategies to cure HIV or control viral infection to overcome the need for life-long antiretroviral therapy.</p>				
091934	<a href="#">Mechanisms and Consequences of Sleep Disparities in the U.S. (R01 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-164	14-Jul-2021	Not Specified
	<p>Contact Name   Rina Das, Ph.D.</p> <p>Contact Telephone   301-496-3996</p> <p>Contact Email   <a href="mailto:dasr2@mail.nih.gov">dasr2@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Jul-2021 , 14-Jul-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to promote research to understand the underlying mechanisms of sleep deficiencies among U.S. populations that experience health disparities and how sleep deficiencies may lead to disparities in health outcomes.</p>				
103844	<a href="#">RFA-DE-22-002 -- Addressing Social Determinants of Health to Eliminate Oral Health Disparities (UG3/UH3 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	RFA-DE-22-002	08-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Hiroko Iida, DDS, MPH</p> <p>Contact Telephone   301-594-7404</p> <p>Contact Email   <a href="mailto:hiroko.iida@nih.gov">hiroko.iida@nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021 , 26-Jul-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support research on how to effectively identify and optimally address upstream social determinants of health that can often present as a barrier to optimal oral health, impede the effectiveness of interventions, and contribute to oral health disparities in vulnerable and underserved groups. To achieve this goal, this FOA will encourage multi-disciplinary collaborations, mechanistic research, multi-level research, and/or the use of systems science research approaches. Applications in response to this FOA must propose research that involves improving oral health outcomes through addressing or better understanding one or more upstream social determinants of health that operate beyond the individual-level of influence (as indicated in the National Institute on Minority Health and Health Disparities Research or Social-Ecological Model frameworks). Study designs appropriate for this FOA would be clinical trials, observational cohort studies, or studies conducting multi-level systems science analyses. Awards made under this FOA will initially support a planning phase (UG3) for up to one year, with possible transition to an implementation phase of up to five years (UH3) for a total of up to six years of funding.</p>				
099865	<p><a href="#">RFA-NS-21-010 -- HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	RFA-NS-21-010	14-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Michael Oshinsky</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email <a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 15-Sep-2021 [Optional][LOI/Pre-App], 15-Oct-2021 , 16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) <a href="https://heal.nih.gov/research/clinical-research/eppic-net">https://heal.nih.gov/research/clinical-research/eppic-net</a> or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.				
103426	<a href="#">RFA-CA-21-029 -- Centers on Telehealth Research for Cancer-Related Care (P50 Clinical Trial Required)</a>	National Institutes of Health/DHHS	RFA-CA-21-029	20-Jun-2021 [Optional][LOI/Pre-App]	4,000,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	<a href="#">Link to program URL</a> 20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to fund P50 Centers dedicated to advancing a national telehealth research agenda focused on improving cancer-related care and outcomes across the cancer control continuum in a rapidly changing healthcare, policy, technology, and communication environment. Centers are expected to generate and disseminate a robust evidence base for patient-centered, sustainable telehealth models of cancer care delivery. Centers will foster innovations to improve cancer care delivery by researching real-time, patient-provider telehealth communication using new tools, research methods, and technologies. Each Center will focus on one overarching cancer-focused telehealth research theme that will frame the Center’s scientific activities. Each Center will leverage a clinical practice network able to support multiple cancer-focused telehealth research studies, including two rapid-cycle pilot projects and one large-scale pragmatic randomized control trial. A centerpiece of each Center, the pragmatic trial will evaluate the integration of telehealth-delivered cancer care into a real-world clinical environment, evaluating improvements in patient access, quality of care, patient-provider communication, and health outcomes. Centers will disseminate evidence-based approaches to telehealth-focused cancer care to the broader clinical care and cancer control communities. Collectively, the P50 Centers on Telehealth Research for Cancer-Related Care will represent a national initiative at the forefront of cancer-related telehealth research committed to improving access to care, care quality, patient-provider communication, and health outcomes across the cancer control continuum.			
103055	<a href="#">RFA-TW-21-001 -- Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (Collaborative U01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-TW-21-001	08-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Christine M. Jessup, Ph.D.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-496-1653				
Contact Email	<a href="mailto:Christine.Jessup@nih.gov">Christine.Jessup@nih.gov</a>				
Sponsor Website					
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021				
Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications for research projects in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats. These hubs are expected to conduct the research and training needed to identify and design mitigation strategies for the adverse consequences of environmental exposures and inform relevant policy development in LMICs. The global network of hubs will serve as a platform for coordinated research and research training. GEOHealth Hubs are expected to provide leadership in environmental and occupational health research and in training a new generation of environmental and occupational health experts. Hubs are supported by two coordinated linked awards to 1) a LMIC institution for research and 2) a U.S. institution for research training. Both applications must demonstrate a commitment to extensive coordination between these two awards to meet goals of the GEOHealth program. An application submitted in response to this FOA for research must be harmonized with a linked application for research training under RFA-TW-21-002 “Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research Training (Collaborative U2R Clinical Trial Optional)”. This research FOA is intended to support collaborative research that contributes to the long-term goals of 1) building and strengthening sustainable research capacity in LMICs to address environmental and occupational health, and 2) developing a research foundation to inform evidence-based policy related to environmental and occupational health. Clinical research (<a href="https://grants.nih.gov/grants/glossary.htm#ClinicalResearch">https://grants.nih.gov/grants/glossary.htm#ClinicalResearch</a>), clinical trials (<a href="https://grants.nih.gov/grants/glossary.htm#ClinicalTrial">https://grants.nih.gov/grants/glossary.htm#ClinicalTrial</a>), and human subjects research (<a href="https://humansubjects.nih.gov/">https://humansubjects.nih.gov/</a>) are allowed under this FOA. Examples of the types of NIH-defined clinical trials that could be proposed include (but are not limited to) technology interventions, behavioral interventions, etc. This FOA will NOT support studies whose purpose is to evaluate safety clinical efficacy, effectiveness, and management and/or implementation of new or established pharmacological agents. For the NIH definition of clinical research versus clinical trials, please see <a href="https://grants.nih.gov/policy/clinical-trials/definition.htm">https://grants.nih.gov/policy/clinical-trials/definition.htm</a>. Please use the clinical trial tool (<a href="https://grants.nih.gov/ct-decision/index.htm">https://grants.nih.gov/ct-decision/index.htm</a>) to determine whether your proposed study is a clinical trial. For additional information please refer to the NIH Clinical Trials Requirements and Fogarty information on human subjects research and clinical trials. Applicants desiring to conduct NIH-defined clinical trials should contact the FIC prior to submission to review the scope of the proposed</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

clinical trial with the program contact. Applicants are strongly encouraged to review the NOT-OD-15-103 on enhancing the reproducibility of NIH-supported research through rigor and transparency and to incorporate appropriate features into the proposed research plans.

103058	<a href="#">RFA-TW-21-002 -- Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research Training (Collaborative U2R Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-TW-21-002	08-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	--	---------------

Contact Name	Christine M. Jessup, Ph.D.
Contact Telephone	301-496-1653
Contact Email	<a href="mailto:Christine.Jessup@nih.gov">Christine.Jessup@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021

**Synopsis** This Funding Opportunity Announcement (FOA) solicits applications for research training activities in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in the Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats. These hubs are expected to conduct the research and training needed to identify and design mitigation strategies for the adverse consequences of environmental exposures and inform relevant policy development in LMICs. The global network of hubs will serve as a platform for coordinated research and research training. GEOHealth Hubs are expected to provide leadership in environmental and occupational health research and in training a new generation of environmental and occupational health experts. Hubs are supported by two coordinated linked awards to 1) a LMIC institution for research and 2) a U.S. institution for research training. Both applications must demonstrate a commitment to extensive coordination between these two awards to meet goals of the GEOHealth program. An application submitted in response to this FOA for research training must be harmonized with a linked application for related research under RFA-TW-21-001 “Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (Collaborative U01 Clinical Trial Optional)”. This research training FOA is intended to support research training of LMIC investigators, provide mentored research training opportunities in the partner LMIC, and strengthen the capacity of the partner LMIC institution to conduct environmental and occupational health research. This Funding Opportunity Announcement (FOA) allows appointment of Trainees proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		investigator, as part of their research and career development.			
088687	<a href="#">Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-107	28-Jul-2021	5,000,000 USD
	<p>Contact Name   Candice Beaubien, M.P.H.</p> <p>Contact Telephone   240-627-3098</p> <p>Contact Email   <a href="mailto:candice.beaubien@nih.gov">candice.beaubien@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Jul-2021 , 28-Jul-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. Additionally, D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.</p>				
103292	<a href="#">RFA-NS-21-013 -- BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-21-013	07-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Karen K David, PhD</p> <p>Contact Telephone   301-496-9964</p> <p>Contact Email   <a href="mailto:BRAINcircuits@NIH.GOV">BRAINcircuits@NIH.GOV</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jun-2021 [Optional][LOI/Pre-App], 07-Jul-2021 , 11-Oct-2021 [Optional][LOI/Pre-App], 10-Nov-2021</p> <p>Synopsis   This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative).</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.</p>					
103295	<a href="#">RFA-NS-21-014 -- BRAIN Initiative: Targeted BRAIN Circuits Planning Projects – TargetedBCPP (R34 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-21-014	07-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Karen K David, PhD            Contact Telephone   301-496-9964            Contact Email   <a href="mailto:BRAINcircuits@NIH.GOV">BRAINcircuits@NIH.GOV</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jun-2021 [Optional][LOI/Pre-App], 07-Jul-2021 , 11-Oct-2021 [Optional][LOI/Pre-App], 10-Nov-2021            Synopsis   This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-21-013). Applications should be adventurous exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.</p>				
089643	<a href="#">National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Substance Use Disorders, or Alcohol Use Disorder (U19 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-119	26-Jul-2021	Not Specified
	<p>Contact Name   Linda Brady, Ph.D., Director            Contact Telephone   301-443-3563            Contact Email   <a href="mailto:lbrady@mail.nih.gov">lbrady@mail.nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   26-Jul-2021 , 26-Nov-2021 , 25-Mar-2022            Synopsis   The purpose of this FOA is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol use disorder (AUD); develop</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, SUDs or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, SUDs or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion FOA at PAR-20-118.</p>			
090063	<a href="#">Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-20-125	24-Jun-2021	4,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Sheila A. Caldwell, PhD</p> <p><a href="mailto:caldwells@mail.nih.gov">caldwells@mail.nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>24-Jun-2021 , 23-Jul-2021</p> <p>The National Institute of General Medical Sciences, in conjunction with the Institutes/Centers of the National Institutes of Health (NIH) listed above in the "Components of Participating Organizations" section and the Indian Health Service (IHS), invites applications from federally recognized Tribes and Tribal organizations for the Native American Research Centers for Health (NARCH) initiative. The objective of the NARCH initiative is to support biomedical research and career enhancement opportunities to meet health needs prioritized by American Indian/Alaska Native (AI/AN) communities. The NARCH initiative also supports research capacity building and the development of research infrastructure to enhance the biomedical research capabilities of AI/AN communities.</p>			
088686	<a href="#">Centers for AIDS Research (P30 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-106	28-Jul-2021	Not Specified
	Contact Name	Candice Beaubien, M.P.H.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-627-3098</p> <p>Contact Email   <a href="mailto:candice.beaubien@nih.gov">candice.beaubien@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Jul-2021 , 28-Jul-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.</p>				
102984	<p><a href="#">RFA-AT-21-006 -- Neural Mechanisms of Force-Based Manipulations: High Priority Research Networks (U24 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	RFA-AT-21-006	14-Jun-2021 [Optional][LOI/Pre-App]	2,000,000 USD
	<p>Contact Name   Merav Sabri, Ph.D.</p> <p>Contact Telephone   301-496-2583</p> <p>Contact Email   <a href="mailto:merav.sabri@nih.gov">merav.sabri@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits applications that focus on developing resources to refine and test key concepts that will advance and further support study on the neural mechanisms and biomechanics of force-based manipulations. This grant funding initiative will support resources and activities such as research network meetings, conferences, small-scale pilot research, multidisciplinary cross training (e.g., intensive workshops, summer institutes, or visiting scholar programs), and information dissemination to foster the growth and development of research on the neural mechanisms and biomechanics of force-based manipulations. Further details and a description of priority areas are provided in this FOA.</p>				
089640	<p><a href="#">National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PAR-20-118	26-Jul-2021	Not Specified
	<p>Contact Name   Linda Brady, Ph.D., Director</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-443-3563</p> <p>Contact Email   <a href="mailto:lbrady@mail.nih.gov">lbrady@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   26-Jul-2021 , 26-Nov-2021 , 25-Mar-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion FOA at PAR-20-119 . This FOA supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.</p>				
078592	<a href="#">Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-19-070	09-Jul-2021	Not Specified
	<p>Contact Name   Robin A. Barr, D.Phil.</p> <p>Contact Telephone   301-402-7715</p> <p>Contact Email   <a href="mailto:BarrR@mail.nih.gov">BarrR@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   09-Jul-2021 , 12-Nov-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

through a series of Notices published subsequent to this FOA.

104041	<a href="#">RFA-NS-21-023 -- BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-21-023	01-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	--	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Brooks Gross, PhD</p> <p>301-496-1447</p> <p><a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>01-Jun-2021 [Optional][LOI/Pre-App], 01-Jul-2021 , 20-Sep-2021 [Optional][LOI/Pre-App], 20-Oct-2021 , 19-Jan-2022 [Optional][LOI/Pre-App], 18-Feb-2022 , 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022 , 18-Sep-2022 [Optional][LOI/Pre-App], 18-Oct-2022 , 22-Jan-2023 [Optional][LOI/Pre-App], 21-Feb-2023 , 20-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023 , 18-Sep-2023 [Optional][LOI/Pre-App], 18-Oct-2023 , 21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study, as well as a subsequent small clinical study. Only Significant Risk (SR) clinical studies that will require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-21-024 or this FOA. The BRAIN PPP includes agreements with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new FDA IDE and IRB approvals without need for significant additional non-clinical data. For more information on the BRAIN PPP, see <a href="https://braininitiative.nih.gov/brain-programs/public-private-partnerships">https://braininitiative.nih.gov/brain-programs/public-private-partnerships</a></p>
---	---

104028	<a href="#">RFA-AI-21-039 -- Consortium for Innovative HIV/AIDS Vaccine and Cure</a>	National Institutes of	RFA-AI-21-039	05-Jul-2021	Not
--------	--	------------------------	---------------	-------------	-----

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Research (UM1 Clinical Trial Not Allowed)</a>		Health/DHHS	[Optional][LOI/Pre-App]	Specified
	<p>Contact Name   Nancy Miller, Ph.D.</p> <p>Contact Telephone   240-292-6178</p> <p>Contact Email   <a href="mailto:nmiller@niaid.nih.gov">nmiller@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jul-2021 [Optional][LOI/Pre-App], 04-Aug-2021</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to support consortia to conduct research toward the prevention and cure of HIV. The Consortium for Innovative HIV Vaccine and Cure Research will establish a collaborative and integrated research program built around two areas of scientific focus: identification of the correlates and the mechanism(s) of protection of preventive vaccine(s) and the use of vaccines or other immune modalities in advancing cure research. Preclinical studies in nonhuman primate (NHP) models will be supported to investigate the mechanism(s), by which efficacious AIDS vaccines protect NHPs from initial infection or establishment of systemic infection, and will incorporate vaccines or other immune interventions into cure strategies in SIV or SHIV-infected NHPs with the objective of eliminating virus reservoirs or establishing elite control of virus replication. Research findings can be applied to improve HIV vaccines and cure strategies and further advancement toward evaluation in human clinical trials.</p>				
104065	<a href="#">FCO -- Syphilis Specimen Collection</a>		National Institutes of Health/DHHS	75N93021R00005 01-Jul-2021	Not Specified
	<p>Contact Name   Aytaj Vily</p> <p>Contact Telephone   301-761-5131</p> <p>Contact Email   <a href="mailto:aytaj.vily@nih.gov">aytaj.vily@nih.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL  </p> <p>Deadline Dates (ALL)   01-Jul-2021</p> <p>Synopsis   Description Introduction: The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Enteric and Sexually Transmitted Infections Branch (ESTIB) has a requirement for the design and performance of a longitudinal, multisite clinical</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104043	<a href="#">RFA-NS-21-024 -- BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-21-024	01-Jun-2021 [Optional][LOI/Pre-App]	Not Specified

study that will enroll untreated patients who have primary, secondary or early latent syphilis. Description: Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS) strives to understand, treat and ultimately prevent the myriad of infectious and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control and prevent diseases caused by infectious agents. This includes basic and applied research to develop and evaluate therapeutics, vaccines, and diagnostics, which are funded through a variety of research grants and contracts. The NIAID Enteric and Sexually Transmitted Infections Branch supports research in bacterial enteric pathogens and sexually transmitted infections (STIs). Syphilis is an STI caused by the bacterial pathogen *Treponema pallidum*. The number of syphilis cases, especially congenital syphilis, has significantly increased nationally in the last five years. The CDC reported over 100,000 cases of syphilis in the U.S. in 2018, which is a 14% increase from 2017, and that year there was also a 40% rise in cases of congenital syphilis. Therefore, urgent efforts are needed to design and implement control and preventive measures for syphilis. Suboptimal syphilis diagnostics and insufficient information on the human immune response to *T. pallidum* infection pose a critical barrier to syphilis efforts. Most cases of syphilis are diagnosed by using a screening algorithm involving multiple serum antibody tests, all with imperfect specificity and sensitivity. Although these tests have been used in some fashion since the 1930s, they have well-known limitations including the inability to reliably distinguish between current and past infections, and difficulty in determining cure after antibiotic administration. In the past few decades, modern molecular techniques such as nucleic acid amplification systems and platforms, transcriptomics, proteomics and metabolomics have been developed and successfully applied to diagnosis of infectious diseases. However, developers of potential syphilis diagnostics have little to no access to high-quality syphilis patient specimens for advancing product development. This RFP is intended to fill this gap and facilitate efforts towards syphilis control, prevention and ultimately elimination. The 16-month contract Base will include protocol development, activation of multiple clinical sites, protocol implementation and the collection and delivery of specimens from a minimum of 50 patients with confirmed syphilis, or possibly have serofast status, who complete the protocol. Three 10-month Options will be for the collection of specimens from a minimum of 75 syphilis patients per option. The number and identity of participating clinical sites shall be determined by the contractor. The contractor also shall institute a panel of syphilis experts that will evaluate each patient's clinical data and adjudicate the final diagnosis and stage of disease (primary, secondary or early latent syphilis, along with a subset of serofast patients if proposed). The contractor shall send specimens to an NIAID-supported repository from patients who have completed the study along with all metadata that includes, but is not limited to, the adjudication of the expert panel and results from all syphilis-related and other pertinent diagnostic/medical tests.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Brooks Gross, PhD</p> <p>301-496-1447</p> <p><a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>01-Jun-2021 [Optional][LOI/Pre-App], 01-Jul-2021 , 20-Sep-2021 [Optional][LOI/Pre-App], 20-Oct-2021 , 19-Jan-2022 [Optional][LOI/Pre-App], 18-Feb-2022 , 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022 , 18-Sep-2022 [Optional][LOI/Pre-App], 18-Oct-2022 , 22-Jan-2023 [Optional][LOI/Pre-App], 21-Feb-2023 , 20-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023 , 18-Sep-2023 [Optional][LOI/Pre-App], 18-Oct-2023 , 21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue first-in-human or early stage clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Only Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA. The clinical study is expected to provide data to answer key questions about the function or final design of a device and is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is part of a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. As part of the BRAIN Initiative, NIH has initiated a Public-Private Partnership Program (BRAIN PPP) that includes agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new FDA IDE and IRB approvals without need for significant additional non-clinical data. For more information on the BRAIN PPP, see <a href="https://braininitiative.nih.gov/brain-programs/public-private-partnerships">https://braininitiative.nih.gov/brain-programs/public-private-partnerships</a> Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-21-023 or this FOA.</p>
---	---

078618	<a href="#">Data Science Research: Personal Health Libraries for Consumers and Patients (R01 Clinical Trial Optional)</a>	National Library of Medicine/NIH/DHHS	PAR-19-072	30-Jun-2021 [Optional][LOI/Pre-App]	1,000,000 USD
--------	---	---------------------------------------	------------	--	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Alan VanBiervliet, Ph.D.</p> <p>301-594-4882</p> <p><a href="mailto:vanbiervliet@nih.gov">vanbiervliet@nih.gov</a></p>
---	---

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website					
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021				
Synopsis	The National Library of Medicine seeks applications for novel informatics and data science approaches that can help individuals gather, manage and use data and information about their personal health. A goal of this program is to advance research and application by patients and the research community through broadly sharing the results via publication, and through open source mechanisms for data or resource sharing.				



## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
087457	<a href="#">Faculty Early Career Development (CAREER) Program</a>	National Science Foundation	20-525	26-Jul-2021	400,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-292-5111</p> <p>Contact Email <a href="mailto:info@nsf.gov">info@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 26-Jul-2021</p> <p>Synopsis</p> <p>CAREER: The Faculty Early Career Development (CAREER) Program is a Foundation-wide activity that offers the National Science Foundation's most prestigious awards in support of early-career faculty who have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization. Activities pursued by early-career faculty should build a firm foundation for a lifetime of leadership in integrating education and research. NSF encourages submission of CAREER proposals from early-career faculty at all CAREER-eligible organizations and especially encourages women, members of underrepresented minority groups, and persons with disabilities to apply. Each year NSF selects nominees for the Presidential Early Career Awards for Scientists and Engineers (PECASE) from among the most meritorious recent CAREER awardees. Selection for this award is based on two important criteria: 1) innovative research at the frontiers of science and technology that is relevant to the mission of NSF, and 2) community service demonstrated through scientific leadership, education, or community outreach. These awards foster innovative developments in science and technology, increase awareness of careers in science and engineering, give recognition to the scientific missions of the participating agencies, enhance connections between fundamental research and national goals, and highlight the importance of science and technology for the Nation's future. Individuals cannot apply for PECASE. These awards are initiated by the participating federal agencies. At NSF, up to twenty nominees for this award are selected each year from among the PECASE-eligible CAREER awardees most likely to become the leaders of academic research and education in the twenty-first century. The White House Office of Science and Technology Policy makes the final selection and announcement of the awardees.</p>				
103909	<a href="#">Disrupting Operations of Illicit Supply Networks (D-ISN)</a>	National Science Foundation	21-582	28-Jul-2021	1,000,000 USD
	<p>Contact Name Georgia-Ann Klutke</p> <p>Contact Telephone 703-292-2443</p> <p>Contact Email <a href="mailto:gaklutke@nsf.gov">gaklutke@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p>				

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 28-Jul-2021 , 22-Apr-2022

Synopsis | Criminal networks that illegally traffic in everything from people and drugs to human organs, natural resources and nuclear material pose grave threats to the health, prosperity and security of our Nation. As an important example, the opioid epidemic in the United States has largely been fueled by new synthetic opioids that are primarily produced in overseas facilities and distributed to the US through intermediate countries. These illicit supply chains flourish across national boundaries, both taking advantage of and contributing to regional instability. The profits generated through these activities finance ongoing conflicts across the globe. Making use of the same communications, logistics, transportation, and financial infrastructure that enable globally integrated commercial supply chains, illicit flows are now estimated to account for 4-6% of global GDP, or roughly \$2 trillion annually. Moreover, these networks use exploitative labor, such as child labor, forced labor and human trafficking, to source and produce goods and services that contribute to both illicit and legal commercial supply chains. The Disrupting Operations of Illicit Supply Networks (D-ISN) Solicitation supports research projects that take a systems approach to advance fundamental understanding of how networks that traffic in illicit or illicitly-produced goods and services operate, leading to technological breakthroughs that bolster our ability to disable these networks.

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104111	<a href="#">Family-Centered Approaches to Improving Type 2 Diabetes Control and Prevention</a>	Assistant Secretary for Health/DHHS	MP-CPI-21-001	13-Jul-2021	1,500,000 USD
	Contact Name	Duane Barlow			
	Contact Telephone	240-453-8822			
	Contact Email	<a href="mailto:Duane.Barlow@hhs.gov">Duane.Barlow@hhs.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Jul-2021			
	Synopsis	<p>This notice solicits applications to fund projects that test interventions to identify family-centered factors that promote self-management and prevention of Type 2 diabetes among racial and ethnic minority and disadvantaged families who have a member(s) aged 12 and older with Type 2 diabetes. Through the testing of family-centered interventions, OMH expects the FamilyCentered Approaches to Improving Type 2 Diabetes Control and Prevention initiative to identify specific family-centered factors (e.g., structural, instrumental, functional, cultural and social needs) that affect patient self-management of diabetes (e.g., physical activity, healthy nutrition) and family members' health outcomes. The target population for the intervention is racial/ethnic minority and disadvantaged families with a family member(s) aged 12 and older with Type 2 diabetes. For the purposes of this notice, "family" also includes persons who may live in the same household as the individual with Type 2 diabetes.</p>			
103543	<a href="#">Research on Research Integrity Conferences</a>	Assistant Secretary for Health/DHHS	IR-ORI-21-002	01-Jul-2021	50,000 USD
	Contact Name	Stephen Gonsalves			
	Contact Telephone	240-453-8400			
	Contact Email	<a href="mailto:Stephen.Gonsalves@hhs.gov">Stephen.Gonsalves@hhs.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jul-2021			
	Synopsis	<p>This notice solicits applications for projects to plan and implement conferences or workshops on research integrity and compliance with 42 C.F.R. Part 93. Virtual conferences, and workshops will be eligible for funding.</p>			
104180	<a href="#">Shoulder to Shoulder: Accompanying Ministries of Health</a>	Center for Global	CDC-RFA-GH21-2164	16-Jul-2021	210,000,000 USD

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">in Central America in Strengthening Local and Global Health Security</a>	Health/CDC/DHHS			
	<p>Contact Name   JoDe Baker, Project Officer</p> <p>Contact Telephone   404-498-4429</p> <p>Contact Email   <a href="mailto:czw9@cdc.gov">czw9@cdc.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jul-2021</p> <p>Synopsis   This NOFO will provide opportunities for a partner to work closely with the CDC regional office in Central America, local and national public health programs, and other partners to strengthen key systems needed to enhance global health security and improve compliance with the revised International Health Regulations (IHR)2005, among the eight countries of the Central America Region. The CDC Central American Region (CAR) for Division for Global Health Protection (DGHP) covers 8 countries (Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and the Dominican Republic).</p>				
103018	<a href="#">Peer Reviewed Cancer Research Program--Behavioral Health Science Award</a>	Department of the Army	W81XWH-21-PRCRP-BHSA	29-Jul-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone   301-682-5507</p> <p>Contact Email   <a href="mailto:help@eBRAP.org">help@eBRAP.org</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   29-Jul-2021 [LOI/Pre-App], 18-Aug-2021</p> <p>Synopsis   The Behavioral Health Science Award supports innovative research and high-reward studies that span the spectrum of behavioral health science, including quality of life, symptom management, resilience, neurocognitive deficits, and psychosocial issues related to cancer diagnosis, treatment, and survivorship. Studies must address one or more of these critical issues in at least one of the FY21 PRCRP Topic Areas. Proposed research should focus on at least one of the stages of survivorship as characterized by the American Society for Clinical Oncology: acute, extended, and/or permanent. The overall goal of the Behavioral Health Science Award is to advance behavioral health cancer science and fill gaps in the understanding of survivorship, including investigations into the psychological health and well-being of those affected by cancer (e.g., patients, family</p>				

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103309	<p>members). This may include investigations into studies that improve mental health and/or cancer-related outcomes in defined populations. Studies also may assess the relationship(s) between behavioral and social functioning in relation to cancer initiation, progression, detection, treatment, and rehabilitation. Applications may propose behavioral science that examines quality of life studies, decision-making and/or cognitive function research, development and testing of educational interventions, and symptom management (e.g., toxicity of treatment, palliative care, psychological distress and anxiety). Applications may target development of evidence-based practices, behavioral health science interventions and surveillance, and identification of psychosocial patient outcomes. The critical components of this award mechanism are:</p> <ul style="list-style-type: none"> <li>· <b>Impact:</b> The Behavioral Health Science Award is intended to support research that demonstrates the potential to have a major impact on patient outcomes, especially during the three stages of survivorship (acute, extended, and/or permanent). The proposed study must demonstrate how the research will transform behavioral health outcomes related to at least one of the FY21 PRCRP Topic Areas. Research should challenge paradigms with respect to impact on patient care and outcomes. Proposed projects may include translational or clinical research, including pilot clinical trials. Impactful research will, if successful, accelerate the movement of promising ideas into clinical applications and advance the behavioral health science in the area of survivorship.</li> <li>· <b>Study Design:</b> Applications should clearly articulate the chosen design of the study. Basic studies should demonstrate research strategy, feasibility, and how the study relates to the human experience with cancer. Studies entailing retrospective or prospective recruitment should define the type of architecture of the study (e.g., descriptive, correlational, field experimental, meta-analyses). Study populations should be defined. The rationale should support the chosen study design with statistical evaluation to back the design. Survey instruments should be described in detail.</li> <li>· <b>Preliminary Data:</b> The Behavioral Health Science Award will require preliminary data for all studies that propose the active (prospective) recruitment of human subjects. Studies not proposing active recruitment of human subjects are not required to present preliminary data, but should be supported by sound reasoning and relevant literature.</li> <li>· <b>Patient Advocate Participation:</b> Applications to the Behavioral Health Science Award funding opportunity are required to include at least one patient advocate. The research team must include at least one cancer patient advocate who will be integral throughout the planning and implementation of the research project. The patient advocate will be a person living with cancer; a person previously diagnosed with/treated for cancer but who now has no evidence of disease; or a family member or caretaker of someone with cancer. As a lay representative, the patient advocate should be active in a cancer advocacy organization. The patient advocate should be involved in the development of the research question, project design, oversight, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. The role of the patient advocate should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, cancer. At least one patient advocate should have a high level of knowledge of current cancer issues in the selected FY21 PRCRP Topic Area(s).</li> <li>· <b>Military Health:</b> The proposed research must address at least one of the FY21 PRCRP Military Health Focus Areas. The proposed research must be relevant to active-duty Service Members, Veterans, and their beneficiaries. Behavioral health is of particular importance to the military, and applications should demonstrate how the proposed studies will enhance military health and well-being with respect to cancer.</li> </ul>	Department of the Army	W81XWH-21-PCRP-HDRA	15-Jul-2021 [LOI/Pre-App]	Not Specified

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021 [LOI/Pre-App], 29-Jul-2021</p>				
	Synopsis	<p>The Mission of the FY21 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service Members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following FY21 PCRP Overarching Challenges: Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer--Applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness. Studies should consider both short- and long-term quality of life outcomes. Areas of particular interest include: The mental and emotional health of patients and their families/caregivers Impact of quality of life considerations on decision-making after diagnosis and/or treatment Identification of vulnerable groups of men and their families at great risk of quality of life detriments Translation of factors or interventions that improve quality of life outcomes and overall health and wellness Develop treatments that improve outcomes for men with lethal prostate cancer--Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer. Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer and/or biochemical recurrence. Advance Health Equity and Reduce Disparities in Prostate Cancer--Applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. Inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors. Health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. High-risk populations include, but are not limited to, people of African descent (including Caribbean), genetically predisposed populations, Service Members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities. Define the biology of lethal prostate cancer to reduce death--Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer. Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence. The FY21 PCRP Health Disparity Research Award supports promising</p>			

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>research ideas that have high potential to make a significant impact in eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship. Applications for this award are encouraged to be relevant to one or more of the FY21 PCRP Health Disparity Research Award Focus Areas and must explicitly state how the proposed research is related to the selected focus area(s). If the proposed project does not address one of the FY21 PCRP Health Disparity Research Award Focus Areas, the application must provide a description to justify how the project will nevertheless address a critical disparity-related need within the context of the FY21 PCRP Overarching Challenges. Applications are encouraged from a spectrum of disciplines, including but not limited to basic science, engineering, bioinformatics, population science, psycho-oncology, translational research, health care services.</p>			
103293	<a href="#">DoD Prostate Cancer Research Program - Translational Science Award</a>	Department of the Army	W81XWH-21-PCRP-TSA	15-Jul-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jul-2021 [LOI/Pre-App], 29-Jul-2021			
	Synopsis	<p>The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research. The Mission of the FY21 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service Members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following FY21 PCRP Overarching Challenges: Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer--Applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness. Studies should consider both short- and long-term quality of life outcomes. Areas of particular interest include: The mental and emotional health of patients and their families/caregivers Impact of quality of life considerations on decision-making after diagnosis and/or treatment Identification of vulnerable groups of men and their families at great risk of quality of life detriments Translation of factors or interventions that improve quality of life outcomes and overall health and wellness Develop treatments that improve outcomes for men with lethal prostate cancer-- Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and</p>			

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>metastatic prostate cancer. Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer and/or biochemical recurrence. Advance Health Equity and Reduce Disparities in Prostate Cancer--Applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. Inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors. Health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. High-risk populations include, but are not limited to, people of African descent (including Caribbean), genetically predisposed populations, Service Members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities. Define the biology of lethal prostate cancer to reduce death--Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer. Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.</p>			
103801	<a href="#">Bone Marrow Failure Research Program-- Idea Development Award</a>	Department of the Army	W81XWH-21-BMFRP-IDA	09-Jul-2021 [LOI/Pre-App]	450,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Jul-2021 [LOI/Pre-App], 12-Oct-2021			
	Synopsis	<p>The objective of the FY21 BMFRP is to fund scientifically meritorious research focused on BMF diseases. Investigator-initiated research is encouraged in the areas of congenital or acquired BMF. Studies focused on BMF syndromes and their progression to other malignancies, such as leukemia, are acceptable. However, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. Stem cell biology studies, and translational projects, including bone marrow transplantation studies should be clearly related to BMF diseases. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. The BMFRP Idea Development Award is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP's vision of understanding and curing BMF diseases. This award mechanism is designed to support new ideas. Proposed research studies should have a high probability of revealing new avenues of investigation. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and</p>			



## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
articulated research approach. Personnel on the proposed team should have a strong background in BMF disease research.					
094274	<a href="#">Kidney Cancer Research Program--Concept Award</a>	Department of the Army	W81XWH-21-KCRP-CA	22-Jun-2021 [LOI/Pre-App]	75,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Jun-2021 [LOI/Pre-App], 13-Jul-2021			
	Synopsis	<p>The FY21 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.</p>			
102437	<a href="#">Lung Cancer Research Program--Investigator-Initiated Translational Research Award</a>	Department of the Army	W81XWH-21-LCRP-IITRA	28-Jul-2021	600,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	28-Jul-2021			
	Synopsis	<p>The FY21 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery,</p>			

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:</p> <ul style="list-style-type: none"> <li>· Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts.</li> <li>· Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission.</li> <li>· Correlative studies that are associated with an open/ongoing or completed clinical trial and projects that develop endpoints for clinical trials.</li> </ul> <p>Preliminary lung cancer relevant data to support the feasibility of the research hypotheses and research approaches are required.</p>			
103012	<a href="#">Peer Reviewed Cancer Research Program--Career Development Award</a>	Department of the Army	W81XWH-21-PRCRP-CDA	29-Jul-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Jul-2021 [LOI/Pre-App], 18-Aug-2021			
	Synopsis	<p>The PRCRP is seeking to advance cancer research through development of early-career investigators. Depending on the accomplishments of the candidates, the PRCRP offers two distinct early-career development options for the Career Development Award: the Fellow Option and the Virtual Cancer Center Scholar Option. The PRCRP is not offering the Career Development Award – Virtual Cancer Center Scholar Option in FY21. Applicants applying to the FY21 Career Development Award must apply through the Fellow Option only. Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI’s research and career development. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated. This award supports impactful research projects with an emphasis on discovery. The FY21 Career Development Award – Fellow Option supports independent, early-career investigators (referred to as Fellows) to conduct impactful research with the guidance of an experienced cancer researcher (i.e., Career Guide) and presents an opportunity for Fellows to obtain the funding, guidance, and experience necessary for productive, independent careers at the forefront of cancer research. The goal of the PRCRP is to improve quality of life by decreasing the impact of cancer on active-duty Service Members, their families, Veterans, and the American public. The PRCRP is charged by Congress with the mission to investigate cancer risks and knowledge gaps that may be relevant to active-duty Service Members, their families, other</p>			

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		military beneficiaries, and the American public.			
103795	<a href="#">Bone Marrow Failure Research Program-- Investigator-Initiated Research Award</a>	Department of the Army	W81XWH-21-BMFRP-IIRA	09-Jul-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Jul-2021 [LOI/Pre-App], 12-Oct-2021			
	Synopsis	The objective of the FY21 BMFRP is to fund scientifically meritorious research focused on BMF diseases. Investigator-initiated research is encouraged in the areas of congenital or acquired BMF. Studies focused on BMF syndromes and their progression to other malignancies, such as leukemia, are acceptable. However, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. Stem cell biology studies, and translational projects, including bone marrow transplantation studies should be clearly related to BMF diseases. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.			
103719	<a href="#">Kidney Cancer Research Program Academy of Kidney Cancer Investigators – Postdoctoral and Clinical Fellowship Award</a>	Department of the Army	W81XWH-21-KCRP-PCFA	22-Jun-2021 [LOI/Pre-App]	195,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Jun-2021 [LOI/Pre-App], 13-Jul-2021 , 15-Jul-2021			
	Synopsis	The FY21 KCRP Postdoctoral and Clinical Fellowship Award supports recent doctoral or medical school graduates in pursuit of innovative, high-impact kidney cancer research during their postdoctoral and/or clinical fellowship and allows them to obtain the necessary experience for an independent career as a leader in kidney cancer research. Applicants must demonstrate that the proposed research has high potential to lead to, or make, significant advancements in kidney cancer research and/or			

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	patient care. Applicants for this award must also exhibit a strong desire to pursue a career in kidney cancer research, with clear evidence for a researcher development plan that will lead to a successful independent career in kidney cancer.				
104178	<a href="#">Vision Research Program--Focused Translational Team Science Award</a>	Department of the Army	W81XWH-21-VRP-FTTSA	21-Jul-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	21-Jul-2021 [LOI/Pre-App], 16-Nov-2021			
	Synopsis	The FY21 VRP FTTSA is intended to support a highly collaborative and translational team initiative that will fundamentally advance the understanding and treatment of eye injury and/or visual dysfunction that result from a military-relevant traumatic event (e.g., blast, blunt, thermal, chemical, directed energy trauma). New for FY21: Applicants are encouraged to leverage resources and expertise at the National Center for Advancing Translational Sciences (NCATS) to improve efficiency and accelerate the translational process.			
104172	<a href="#">Vision Research Program--Translational Research Award</a>	Department of the Army	W81XWH-21-VRP-TRA	21-Jul-2021 [LOI/Pre-App]	1,000,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	21-Jul-2021 [LOI/Pre-App], 16-Nov-2021			
	Synopsis	The FY21 VRP TRA is intended to support translational research that moves promising discoveries into clinical applications that will advance the prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military-relevant trauma. Successful applications to the FY21 VRP TRA should establish a clear path to transform a discovery into new drugs, devices, or clinical practice guidelines that are ready for definitive testing in clinical trials. It is expected that, if applicable, an Investigational New Drug (IND)/ Investigational Device Exemption (IDE) application will be submitted during			

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>or by the end of the period of performance. To facilitate the preparation for IND/IDE application, the investigative team should include at least one collaborator with expertise in the U.S. Food and Drug Administration (FDA) regulatory approval process.</p>			
102255	<a href="#">Amyotrophic Lateral Sclerosis Research Program-- Therapeutic Idea Award</a>	Department of the Army	W81XWH-21-ALSRP-TIA	15-Jul-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021</p> <p>Synopsis The FY21 ALSRP Therapeutic Idea Award supports hypothesis-driven therapeutic development and is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Development and/or modification of preclinical model systems or the application of high-throughput screens to define or assess lead compounds for ALS treatment may also be proposed. All research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Preliminary data are not required. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative approach. Projects that focus primarily on investigating the pathophysiology of ALS, without consideration of therapeutic development, are not within the scope of this Funding Opportunity.</p>				
102257	<a href="#">Amyotrophic Lateral Sclerosis Research Program-- Therapeutic Development Award</a>	Department of the Army	W81XWH-21-ALSRP-TDA	15-Jul-2021	1,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email <a href="mailto:help@cdmrp.org">help@cdmrp.org</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021</p>				

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The FY21 ALSRP Therapeutic Development Award supports research ranging from validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited ALS experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints, and pathophysiology.			
104173	<a href="#">Vision Research Program--Clinical Trial Award</a>	Department of the Army	W81XWH-21-VRP-CTA	21-Jul-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	21-Jul-2021 [LOI/Pre-App], 16-Nov-2021			
	Synopsis	The FY21 VRP CTA supports the rapid implementation of early-phase clinical trials (i.e., phase 0 through phase 2a) of new interventions with the potential to have a significant impact on service-connected eye injury and visual dysfunction. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Funding from this award mechanism must support a clinical trial. The FY21 VRP challenges the scientific community to design innovative research that will significantly advance the understanding, prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military-relevant trauma. Research outcomes are expected to ultimately improve the care of Service Members and Veterans as well as the American public.			
104166	<a href="#">Vision Research Program--Investigator- Initiated Research Award</a>	Department of the Army	W81XWH-21-VRP-IIRA	21-Jul-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	21-Jul-2021 [LOI/Pre-App], 16-Nov-2021			

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The FY21 VRP IIRA is intended to support studies that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma. Applications involving multidisciplinary collaborations among academia, industry, the military services, the VA, and other federal government agencies are highly encouraged. To support research projects at different stages and the exploration/development of ideas of different maturity levels, two different funding levels are available under this program announcement. When submitting the pre-application, it is the responsibility of the applicant organization to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the stage and maturity level of the research project, rather than the amount of the budget.</p>			
103989	<a href="#">Water Toxicity Sensor Challenge</a>	Environmental Protection Agency	9934332	26-Jul-2021	15,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:Innovation@epa.gov">Innovation@epa.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	26-Jul-2021			
	Synopsis	<p>To help meet the need for better ways to monitor toxicity in water, EPA and partners are launching the Water Toxicity Sensor Challenge. The challenge calls on innovators to develop a sensor that can identify whether there are chemical pollutants and natural toxins in various types of water much faster and less expensively than current lab methods for detecting individual, specific chemicals. Certain chemicals can activate various toxicity pathways inside living cells. This causes a disruption to normal biological processes, like breathing or digestion, which can lead to harmful health effects such as diseases like cancer.</p>			
103766	<a href="#">Notice of Special Interest (NOSI): Add COVID-19 Capacity Building Grants to PAR-18-604 Vet-LIRN Network Capacity-Building Projects (Vet-LIRN)</a>	Food and Drug Administration/DHHS	NOT-FD-21-014	12-Jul-2021	Not Specified
	Contact Name	Rene Vasquez, Grants Management Specialist			
	Contact Telephone	301-796-3546			
	Contact Email	<a href="mailto:rene.vasquez@fda.hhs.gov">rene.vasquez@fda.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	12-Jul-2021 , 11-Jul-2022 , 10-Jul-2023			
	Synopsis	The purpose of this notice is to inform potential applicants to the Veterinary Laboratory Investigation and Response Network (Vet-LIRN), about a special interest in applications focusing on COVID-19 animal diagnostics.			
100207	<a href="#">Loan Repayment Program for Repayment of Health Professions Educational Loans</a>	Indian Health Service/DHHS		15-Jun-2021	Not Specified
	Contact Name	Ms. Jacqueline K. Santiago			
	Contact Telephone	301-443-3396			
	Contact Email				
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2021 , 15-Jul-2021 , 15-Aug-2021 , 15-Sep-2021 , 30-Sep-2021			
	Synopsis	The Indian Health Service (IHS) estimated budget for fiscal year (FY) 2021 includes \$34,800,000 for the IHS Loan Repayment Program (LRP) for health professional educational loans (undergraduate and graduate) in return for full-time clinical service as defined in the IHS LRP policy.			
103236	<a href="#">HERO Appendix F: NASA Human Research Program Omnibus Opportunity</a>	National Aeronautics & Space Administration	80JSC020N0001-OMNIBUS3	29-Jul-2021	150,000 USD
	Contact Name	Jennifer Fogarty, Ph.D. Chief Scientist, Human Research Program			
	Contact Telephone	281-483-6089			
	Contact Email	<a href="mailto:jennifer.fogarty-1@nasa.gov">jennifer.fogarty-1@nasa.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Jul-2021			
	Synopsis	To expedite progress in various research areas in a short period of time, NASA is requesting proposals for short-term investigations or technology development projects that provide innovative approaches to any of the risks and associated knowledge gaps contained in the Human Research Program (HRP) Integrated Research Plan (IRP). Proposers may access the most current Web-based version of the IRP at the Human Research Roadmap (HRR) Web site at <a href="https://humanresearchroadmap.nasa.gov">https://humanresearchroadmap.nasa.gov</a> . The results of these short-term investigations are anticipated to deliver new tools, techniques, or knowledge that could lead to novel breakthroughs addressing one or more of the risks and gaps in the			



## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

IRP. These short-term investigations may provide initial results testing a new scientific approach, or they may provide the initial proof-of-concept for a new technology or method that has not yet been proven as a means to address a risk or gap in the IRP. All short-term investigations are expected to produce novel scientific knowledge or technology development that can stand alone to address a risk or gap in the IRP, but these investigations may also provide the necessary preliminary results to justify a full proposal to a future NASA solicitation.

081835	<a href="#">David B. Larson Fellowship in Health and Spirituality</a>	Library of Congress		15-Jul-2021	60,000 USD
--------	---	---------------------	--	-------------	------------

Contact Name	
Contact Telephone	202-707-3302
Contact Email	<a href="mailto:scholarly@loc.gov">scholarly@loc.gov</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jul-2021
Synopsis	The John W. Kluge Center at the Library of Congress invites qualified scholars to apply for a post-doctoral fellowship in the field of health and spirituality.

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
060608	<a href="#">Research Innovation Collaborations Program</a>	23andme		16-Jul-2021	Not Specified														
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black; padding: 5px;">Contact Name</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Contact Telephone</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:apply.research@23andme.com">apply.research@23andme.com</a></td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">16-Jul-2021</td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Synopsis</td> <td style="padding: 5px;">23andMe endeavors to advance biomedical science through genetic research. The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.</td> </tr> </table>						Contact Name		Contact Telephone		Contact Email	<a href="mailto:apply.research@23andme.com">apply.research@23andme.com</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	16-Jul-2021	Synopsis	23andMe endeavors to advance biomedical science through genetic research. The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.
Contact Name																			
Contact Telephone																			
Contact Email	<a href="mailto:apply.research@23andme.com">apply.research@23andme.com</a>																		
Sponsor Website	<a href="#">Link to sponsor website</a>																		
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	16-Jul-2021																		
Synopsis	23andMe endeavors to advance biomedical science through genetic research. The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.																		
002780	<a href="#">Post Doctoral Fellowship</a>	A-T Children's Project		01-Jul-2021 [LOI/Pre-App]	80,000 USD														
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black; padding: 5px;">Contact Name</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">954-481-6611</td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:grants@atcp.org">grants@atcp.org</a></td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">01-Jul-2021 [LOI/Pre-App], 07-Sep-2021</td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">Synopsis</td> <td style="padding: 5px;">The Post Doctoral Fellowship Award provides competitive support for clinical and translational research related to A-T.</td> </tr> </table>						Contact Name		Contact Telephone	954-481-6611	Contact Email	<a href="mailto:grants@atcp.org">grants@atcp.org</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	01-Jul-2021 [LOI/Pre-App], 07-Sep-2021	Synopsis	The Post Doctoral Fellowship Award provides competitive support for clinical and translational research related to A-T.
Contact Name																			
Contact Telephone	954-481-6611																		
Contact Email	<a href="mailto:grants@atcp.org">grants@atcp.org</a>																		
Sponsor Website	<a href="#">Link to sponsor website</a>																		
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	01-Jul-2021 [LOI/Pre-App], 07-Sep-2021																		
Synopsis	The Post Doctoral Fellowship Award provides competitive support for clinical and translational research related to A-T.																		
093528	<a href="#">Young Investigator Grants</a>	Alex's Lemonade Stand		12-Jul-2021	150,000 USD														
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black; padding: 5px;">Contact Name</td> <td style="padding: 5px;"></td> </tr> </table>						Contact Name													
Contact Name																			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   610-649-3034</p> <p>Contact Email   <a href="mailto:Grants@AlexsLemonade.org">Grants@AlexsLemonade.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jul-2021</p> <p>Synopsis   The Young Investigator grant is a three-year award designed to support early career researchers, such as postdoctoral, clinical fellows or instructors, pursuing promising childhood cancer research ideas. These grants aim to cultivate the best and brightest researchers of the future who demonstrate a commitment to a research career in pediatric cancer. A mentor is required, and a career development plan must be included. The Young Investigator grant offers up to \$50,000 in direct costs per year for three years.</p>				
059708	<a href="#">ADDF-Harrington Scholar Program</a>	Alzheimer's Drug Discovery Foundation		30-Jul-2021	600,000 USD
	<p>Contact Name  </p> <p>Contact Telephone   212-901-8000</p> <p>Contact Email   <a href="mailto:grants@alzdiscovery.org">grants@alzdiscovery.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-Jul-2021</p> <p>Synopsis   The ADDF-Harrington Scholar Program seeks to accelerate translation of innovative research with potential to prevent, treat, or cure Alzheimer's disease. It provides award recipients with both research funding and committed project support by a team of pharmaceutical industry experts.</p>				
033842	<a href="#">Accelerating Drug Discovery for Frontotemporal Degeneration</a>	Alzheimer's Drug Discovery Foundation		28-May-2021 [LOI/Pre-App]	Not Specified

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 212-901-8000</p> <p>Contact Email <a href="mailto:grants@alzdiscovery.org">grants@alzdiscovery.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-May-2021 [LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis                      There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD) and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP). Drug targets in the areas of inflammation and proteostasis will be considered high priority.</p>				

---

055305	<a href="#">Program to Accelerate Clinical Trials (PACT)</a>	Alzheimer's Drug Discovery Foundation		28-May-2021 [LOI/Pre-App]	3,000,000 USD
--------	--	---------------------------------------	--	------------------------------	------------------

	<p>Contact Name</p> <p>Contact Telephone 212-901-8019</p> <p>Contact Email <a href="mailto:grants@alzdiscovery.org">grants@alzdiscovery.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-May-2021 [LOI/Pre-App], 30-Jul-2021 , 01-Oct-2021 [LOI/Pre-App], 03-Dec-2021</p> <p>Synopsis                      The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and</p>				
--	--	--	--	--	--

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.</p>				
055304	<a href="#">Drug Development Program</a>	Alzheimer's Drug Discovery Foundation		28-May-2021 [LOI/Pre-App]	600,000 USD
	<p>Contact Name   Alessio Travaglia, PhD, Scientific Program Officer            Contact Telephone   212-901-7998            Contact Email   <a href="mailto:atravaglia@alzdiscovery.org">atravaglia@alzdiscovery.org</a>            Sponsor Website   <a href="#">Link to sponsor website</a>            Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   28-May-2021 [LOI/Pre-App], 30-Jul-2021 , 01-Oct-2021 [LOI/Pre-App], 03-Dec-2021            Synopsis   The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer's disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application. This funding opportunity prioritizes novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.</p>				
090760	<a href="#">AWS Diagnostic Development Initiative (DDI)</a>	Amazon Web Services		31-Jul-2021 [Optional]	Not Specified
	<p>Contact Name              Contact Telephone              Contact Email   <a href="mailto:aws-pr@amazon.com">aws-pr@amazon.com</a>            Sponsor Website   <a href="#">Link to sponsor website</a>            Program URL   <a href="#">Link to program URL</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 31-Jul-2021 [Optional], 31-Dec-2021</p> <p>Synopsis The Amazon Web Services (AWS) Diagnostic Development Initiative (DDI) is a two-year, \$20M commitment to accelerate research and innovation to advance the collective understanding and detection of COVID-19 and other infectious diseases in order to mitigate current and future outbreaks. AWS is offering AWS Promotional Credits and technical expertise to support the use of AWS services for projects by selected institutions and companies in four program areas: early disease detection, diagnostics, prognosis, and public health genomics.</p>				
081154	<a href="#">Korb-Exford Dry Eye Career Development Grant</a>	American Academy of Optometry		02-Jul-2021	25,000 USD
	<p>Contact Name Jennifer Rubin, Grants and Awards Manager</p> <p>Contact Telephone 321-319-4872</p> <p>Contact Email <a href="mailto:AAOAwards@aoptom.org">AAOAwards@aoptom.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 02-Jul-2021</p> <p>Synopsis The Korb-Exford Dry Eye Career Development Grant is designed to support an individual to further their knowledge in the broad area of dry eye.</p>				
103842	<a href="#">AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship</a>	American Association for Cancer Research		06-Jul-2021 [LOI/Pre-App]	120,000 USD
	<p>Contact Name</p> <p>Contact Telephone 215-446-7280</p> <p>Contact Email <a href="mailto:grants@aacr.org">grants@aacr.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 06-Jul-2021 [LOI/Pre-App], 23-Sep-2021</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship is a joint effort to support and encourage innovative research projects with direct applicability and relevance to ILC and to help establish a successful career path in the field.			
006566	<a href="#">Research and Training Scholarships</a>	American Association of Obstetricians and Gynecologists Foundation		01-Jul-2021	360,000 USD
	Contact Name	Angeles Alvarez Secord			
	Contact Telephone	919-684-3765			
	Contact Email	<a href="mailto:angeles.secord@duke.edu">angeles.secord@duke.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jul-2021			
	Synopsis	The AAOGF and the Foundations of ABOG and SMFM seek to identify future academic physician leaders in the field of Obstetrics and Gynecology and to stimulate their scholarly development, through the support of advanced scientific training. The Scholarship Award is to be used in an academic Department of Obstetrics and Gynecology in the United States or Canada to provide research training and experience for a candidate of proven ability who exhibits significant talent, original thought and evidence of dedication to an academic career. Research training may focus on basic or translational research, disease pathogenesis, clinical diagnostics, interventions and prevention, or epidemiology.			
016202	<a href="#">Physician Scientist Residency Training Award</a>	American Urological Association		29-Jul-2021 [LOI/Pre-App]	225,000 USD
	Contact Name				
	Contact Telephone	410-689-3700			
	Contact Email	<a href="mailto:grantsmanager@auanet.org">grantsmanager@auanet.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 29-Jul-2021 [LOI/Pre-App], 09-Sep-2021</p> <p>Synopsis The Urology Care Foundation Physician Scientist Residency Training Award (PSRTA) was initiated to provide early-career, intensive research training that will develop the skills necessary to enable ambitious and talented urology residents to ultimately succeed as independently funded surgeon scientists. The PSRTA enables a focused and well-defined urology residency research track that will appropriately train carefully selected individuals. Training will be conducted at urologic research centers of excellence with strong infrastructure, mentoring, didactics, and career development elements to best prepare residents for successful and impactful research careers.</p>				
023279	<a href="#">Short-Term Research/Training Fellowship</a>	Asian Pacific Society of Respirology		31-Jul-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone +81-3-5684-3370</p> <p>Contact Email <a href="mailto:apsrinfo@theapsr.org">apsrinfo@theapsr.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 31-Jul-2021 , 30-Nov-2021</p> <p>Synopsis The APSR is funding a scholarship programme with the aims of: promoting science and research in respiratory medicine in the APSR region; supporting the exchange in the APSR region of young scientists and clinicians actively involved in respiratory medicine; and contributing to the development of research and science of respiratory medicine in the APSR region.</p>				
066425	<a href="#">Technologist Travel Award</a>	Association for Molecular Pathology		23-Jul-2021	1,500 USD
	<p>Contact Name</p> <p>Contact Telephone 301-634-7987</p> <p>Contact Email <a href="mailto:amp@amp.org">amp@amp.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 23-Jul-2021</p> <p>Synopsis The AMP Technologist Travel Award provides travel assistance to the Annual Meeting &amp; Expo for up to three (3) selected AMP member technologists who do not receive travel support from their institutions.</p>				
060378	<a href="#">Avian Health Fund Grant</a>	Association of Avian Veterinarians		15-Jul-2021	10,000 USD
	<p>Contact Name</p> <p>Contact Telephone 720-458-4111</p> <p>Contact Email <a href="mailto:grants.awards.scholarships@aav.org">grants.awards.scholarships@aav.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021</p> <p>Synopsis Pre-proposals for research projects addressing clinical aspects of captive bird health (companion and zoological species) are now being accepted for consideration for funding by the Association of Avian Veterinarians (AAV).</p>				
080060	<a href="#">Wild Bird Health Grant</a>	Association of Avian Veterinarians		15-Jul-2021	5,000 USD
	<p>Contact Name</p> <p>Contact Telephone 720-458-4111</p> <p>Contact Email <a href="mailto:office@aav.org">office@aav.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021</p> <p>Synopsis The Association of Avian Veterinarians (AAV) is accepting pre-proposals for research projects addressing wild bird health. Grants are limited to \$5,000 US for individual projects.</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
067925	<a href="#">Grants Program</a>	Barnett (Gordon J) Foundation		31-Jul-2021	20,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:fdnsvcs.fl@suntrust.com">fdnsvcs.fl@suntrust.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	31-Jul-2021			
	Synopsis	The Gordon J. Barnett Memorial Foundation was established for religious, charitable, scientific, literary, and educational purposes or the prevention of cruelty to children or animals.			
079141	<a href="#">Exceptional Project Grants</a>	Breast Cancer Alliance, Inc.		23-Jul-2021	100,000 USD
	Contact Name				
	Contact Telephone	203-861-0014			
	Contact Email	<a href="mailto:researchgrants@breastcanceralliance.org">researchgrants@breastcanceralliance.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	23-Jul-2021			
	Synopsis	Breast Cancer Alliance (BCA) offers Exceptional Project Grants to recognize creative, unique and innovative research. Clinical doctors and research scientists whose primary focus is breast cancer are invited to apply. This is a one year grant for a total of \$100,000.			
059797	<a href="#">Young Investigator Grant Program</a>	Breast Cancer Alliance, Inc.		23-Jul-2021	125,000 USD
	Contact Name				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   203-861-0014</p> <p>Contact Email   <a href="mailto:researchgrants@breastcanceralliance.org">researchgrants@breastcanceralliance.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   23-Jul-2021</p> <p>Synopsis   To encourage a commitment to breast cancer research, Breast Cancer Alliance invites clinical doctors and research scientists, including post docs, whose primary focus is breast cancer and who are in the early stages of their careers, to apply for funding for the Young Investigator Grant. This is a two-year grant for a total of \$125,000, with half the grant award being paid out each year.</p>				
100473	<a href="#">Team Grant: Diabetes Mechanisms and Translational Solutions</a>	Canadian Institutes of Health Research		13-Jul-2021	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone   613-954-1968</p> <p>Contact Email   <a href="mailto:support@cihr-irsc.gc.ca">support@cihr-irsc.gc.ca</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   13-Jul-2021</p> <p>Synopsis   As part of 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes, the Team Grants in Diabetes Mechanisms and Translational Solutions will support multi-disciplinary research to better understand the underlying causes and pathophysiology of diabetes, and develop improved prevention and treatment approaches for diabetes. For the purposes of this Initiative, diabetes includes all forms of diabetes mellitus, its complications and co-morbidities. Mechanistic research is defined as studies designed to understand the pathophysiology of diabetes, its complications and co-morbidities.</p>				
023360	<a href="#">Drug Discovery Initiative Registered Reports (DDI-RR)</a>	Children's Tumor Foundation		08-Jul-2021	85,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Vidya Browder</p> <p>Contact Telephone   646-738-8557</p> <p>Contact Email   <a href="mailto:vbrowder@ctf.org">vbrowder@ctf.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Jul-2021</p> <p>Synopsis   The Drug Discovery Initiative Awards program supports early stage testing of candidate drug therapies for the treatment of neurofibromatosis (NF): NF1, NF2 and schwannomatosis. DDI Awards will provide up to \$40,000 DDI in vitro Awards to fund cell-based preclinical drug testing studies; or up to \$85,000 DDI in vivo Awards to fund animal-based preclinical drug testing studies.</p>				
001440	<a href="#">Career Development Awards</a>	Crohn's & Colitis Foundation of America		20-Jul-2021	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone   646-943-7501</p> <p>Contact Email   <a href="mailto:mmbesch@crohnscolitisfoundation.org">mmbesch@crohnscolitisfoundation.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Jul-2021</p> <p>Synopsis   The goal of the Career Development Award (CDA) is to encourage a career of independent basic and/or clinical investigation in the area of Crohn's disease and ulcerative colitis research.</p>				
000055	<a href="#">Research Fellowship Awards</a>	Crohn's & Colitis Foundation of America		20-Jul-2021	174,750 USD
	Contact Name   Orlando Green				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 646-943-7501</p> <p>Contact Email <a href="mailto:ogreen@crohnscolitisfoundation.org">ogreen@crohnscolitisfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jul-2021</p> <p>Synopsis The Crohn's &amp; Colitis Foundation's Research Fellowship Awards are intended to support individuals in the post-doctoral phase of their career, to develop skills related to basic and/or clinical investigation in the field of inflammatory bowel disease (IBD), or Crohn's disease and ulcerative colitis.</p>				
000628	<a href="#">Senior Research Awards</a>	Crohn's & Colitis Foundation of America		20-Jul-2021	Not Specified
	<p>Contact Name Orlando Green</p> <p>Contact Telephone 646-943-7501</p> <p>Contact Email <a href="mailto:ogreen@crohnscolitisfoundation.org">ogreen@crohnscolitisfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jul-2021</p> <p>Synopsis Senior Research Awards provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources. Support will be provided for proposals relevant to Inflammatory Bowel Disease (IBD) or Crohn's disease and/or ulcerative colitis.</p>				
083322	<a href="#">Crohn's &amp; Colitis Foundation/NASPGHAN IBD Young Investigator Award</a>	Crohn's & Colitis Foundation of America		20-Jul-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 646-943-7505</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:grant@crohnscolitisfoundation.org">grant@crohnscolitisfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jul-2021 , 05-Nov-2021 [LOI/Pre-App], 28-Jan-2022</p> <p>Synopsis This three-year grant, in partnership with the NASPGHAN Foundation and the Crohn's &amp; Colitis Foundation, is available to research fellows or junior faculty. Applications must propose original clinical, translational, epidemiological, or basic scientific research related to pediatric inflammatory bowel disease. Applicants must indicate in their submission for either a Crohn's &amp; Colitis Foundation Career Development or Research Fellowship Award, if they want their award to be considered for the joint Crohn's &amp; Colitis Foundation/NASPGHAN IBD Young Investigator Award.</p>				
063869	<a href="#">Litwin IBD Pioneers Initiative</a>	Crohn's & Colitis Foundation of America		20-Jul-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 646-943-7505</p> <p>Contact Email <a href="mailto:grant@crohnscolitisfoundation.org">grant@crohnscolitisfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jul-2021</p> <p>Synopsis The Litwin IBD Pioneers Initiative supports innovative clinical and translational research projects with the potential to impact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, identification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds innovative pilot research so that scientists can test their initial ideas and generate preliminary data.</p>				
092281	<a href="#">Damon Runyon-Rachleff Innovation Award</a>	Damon Runyon Cancer Research Foundation		01-Jul-2021	400,000 USD
	Contact Name				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	212-455-0520 <a href="mailto:awards@damonrunyon.org">awards@damonrunyon.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 01-Jul-2021 The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Stage 1 award will be for two years, \$200,000 per year (\$400,000 total) with the opportunity for up to two additional years of funding (up to four years total for \$800,000). Stage 2 support for years three and four will be granted to those awardees who demonstrate progress on their proposed research during years one and two of the award.
--	---

004329	<a href="#">Grants Program</a>	Drown (Joseph) Foundation	15-Jul-2021	Not Specified
--------	--------------------------------	---------------------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Alyssa Santino, Program Officer 310-277-4488 x100 <a href="mailto:alyssa@jdrown.org">alyssa@jdrown.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 15-Jul-2021 , 15-Oct-2021 The Joseph Drown Foundation provides support in the areas of education; community, health and social services; medical and scientific research; arts and humanities; and special projects. Tax-exempt organizations, primarily in the state of California, are eligible. The Foundation makes grants for both operating support and program support, but does not make multi-year commitments. Organizations may receive funding up to four years, after which they must take a two-year hiatus.
--	---

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
057992	<a href="#">Simulation Research Grant</a>	Emergency Medicine Residents' Association		15-Jul-2021	500 USD
	Contact Name				
	Contact Telephone	972-550-0920			
	Contact Email	<a href="mailto:awards@emra.org">awards@emra.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jul-2021			
	Synopsis	The purpose of the EMRA Simulation Research Grant is to provide research funding to Emergency Medicine (EM) physician-in-training interested in completing simulation-based projects during residency/medical school.			
103754	<a href="#">EBAA High Impact Research Grant</a>	Eye Bank Association of America		12-Jul-2021	50,000 USD
	Contact Name	Stacey Gardner, Director of Education			
	Contact Telephone	202-775-4999			
	Contact Email	<a href="mailto:stacey@restoresight.org">stacey@restoresight.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jul-2021			
	Synopsis	The Eye Bank Association of America (EBAA) annually provides a High Impact Research Grant to advance innovation and knowledge in sight restoration, eye banking and cornea transplantation. In 2021, EBAA will fund one proposal focused on "Regenerative Therapies for Corneal Diseases" up to \$50,000.			
073397	<a href="#">FARF Scientific Symposium - Poster Awards</a>	Fanconi Anemia Research Fund, Inc.		29-Jul-2021	500 USD
	Contact Name				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 541-687-4658 Contact Email <a href="mailto:info@fanconi.org">info@fanconi.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 29-Jul-2021 Synopsis The Fanconi Anemia Research Fund will award prizes for the best poster submissions to the Fanconi Anemia Research Fund Scientific Symposium.				
102955	<a href="#">Request For Proposals: Pharmacodynamic Biomarker Development</a>	Friedreich's Ataxia Research Alliance		01-Jul-2021 [LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone 484-879-6160 Contact Email <a href="mailto:grants@curefa.org">grants@curefa.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Jul-2021 [LOI/Pre-App] Synopsis The Friedreich's Ataxia Research Alliance (FARA) is issuing a request for proposal (RFP) to support clinical drug development programs in Friedreich's ataxia (FRDA) by promoting the discovery of technologies to measure frataxin or surrogates of frataxin in inaccessible tissues				
036255	<a href="#">Kyle Bryant Translational Research Award</a>	Friedreich's Ataxia Research Alliance		15-Jul-2021	500,000 USD
	Contact Name Contact Telephone 484-879-6160 Contact Email <a href="mailto:grants@curefa.org">grants@curefa.org</a>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 15-Jul-2021  
 Synopsis The Kyle Bryant Translational Research Award is given to proposals focused on pre-clinical and clinical investigations that will advance treatments for Friedreich's Ataxia.

076236	<a href="#">General Research Grants</a>	Friedreich's Ataxia Research Alliance		15-Jul-2021	300,000 USD
--------	---	---------------------------------------	--	-------------	----------------

Contact Name  
 Contact Telephone 484-879-6160  
 Contact Email [info@curefa.org](mailto:info@curefa.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 15-Jul-2021 , 15-Sep-2021  
 Synopsis FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open forums for leading scientists to share their insights, ideas and challenges to advancing treatments for Friedreich's ataxia. The applicant may request a budget of up to \$150,000 per year for one or two years.

006873	<a href="#">Bronya J. Keats International Research Collaboration Award</a>	Friedreich's Ataxia Research Alliance		15-Jul-2021	400,000 USD
--------	--	---------------------------------------	--	-------------	----------------

Contact Name  
 Contact Telephone 484-879-6160  
 Contact Email [grants@curefa.org](mailto:grants@curefa.org)  
 Sponsor Website [Link to sponsor website](#)

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021</p> <p>Synopsis The Bronya J. Keats International Research Collaboration Award honors its namesake for her academic career in understanding the GAA triplet repeat mutation in FA, and her continued role in managing FARA's grant program. Proposals should focus on FA research that relies on international collaboration among investigators in at least two different countries.</p>				
076215	<a href="#">Shaffer Grant</a>	Glaucoma Research Foundation		15-Jul-2021	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 415-986-3162</p> <p>Contact Email <a href="mailto:research@glaucoma.org">research@glaucoma.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021</p> <p>Synopsis The Glaucoma Research Foundation supports new high-impact clinical, epidemiological and laboratory research based on their strategic research goals.</p>				
032594	<a href="#">Scholar-Innovator Grant Program</a>	Harrington Discovery Institute		26-Jul-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 216-983-3472</p> <p>Contact Email <a href="mailto:HDQuestions@HarringtonDiscovery.org">HDQuestions@HarringtonDiscovery.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 26-Jul-2021</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Harrington Scholar-Innovator Award is issuing a call for proposals for the flagship Harrington ScholarInnovator program to recognize physician-scientists whose research has the potential to advance the standard of care. This program provides dedicated support from a project management team and pharmaceutical industry experts, as well as funding of \$100,000 for 2 years.			
058140	<a href="#">Harvard Medical School Fellowship in General Medicine and Primary Care</a>	Harvard Medical School		03-Jul-2021	Not Specified
	Contact Name	Jessica Pham			
	Contact Telephone	617-643-9433			
	Contact Email	<a href="mailto:GIMFellowship@bidmc.harvard.edu">GIMFellowship@bidmc.harvard.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	03-Jul-2021			
	Synopsis	The Harvard Medical School Fellowship in General Medicine and Primary Care offers 2-year academic fellowships to prepare talented physicians for careers in academic medicine. The Program offers each Fellow an appointment at Harvard Medical School and one of its affiliated hospitals or departments. All fellows qualifying for acceptance to the Harvard School of Public Health pursue a rigorous curriculum that can lead to a Master of Public Health or Master of Science degree. Each Fellow is expected to design, conduct, present, and publish several original investigative projects that lay the foundation for future careers as leaders in general medicine and research.			
057289	<a href="#">Mid-Career Research Award</a>	Hemostasis & Thrombosis Research Society, Inc.		26-Jul-2021	216,000 USD
	Contact Name	Dr. Terri Holzen			
	Contact Telephone	414-937-6569			
	Contact Email	<a href="mailto:tholzen@versiti.org">tholzen@versiti.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 26-Jul-2021</p> <p>Synopsis The HTRS Mid-Career Research Award (MCRA) Program provides financial support for mid-career investigators pursuing clinical, translational, or basic science research projects in hemostasis and/or thrombosis. The maximum 2021 MCRA over two years is \$216,000.</p>				
006302	<a href="#">Young Leaders Program Internships</a>	Heritage Foundation		01-Jul-2021	Not Specified
	<p>Contact Name Helena Richardson</p> <p>Contact Telephone 202-546-4400</p> <p>Contact Email <a href="mailto:YoungLeadersProgram@heritage.org">YoungLeadersProgram@heritage.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jul-2021</p> <p>Synopsis The Young Leaders Program promotes the mission of The Heritage Foundation to the next generation by developing and implementing outreach to younger audiences. The Young Leaders Program is a 12-15 week internship program that provides a full educational program while at The Heritage Foundation.</p>				
081163	<a href="#">SWOG/Hope Foundation Impact Award</a>	Hope Foundation for Cancer Research		01-Jul-2021 [LOI/Pre-App]	250,000 USD
	<p>Contact Name Johanna Horn, President &amp; CEO</p> <p>Contact Telephone 734-998-7150</p> <p>Contact Email <a href="mailto:jo@thehopefoundation.org">jo@thehopefoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   01-Jul-2021 [LOI/Pre-App], 01-Sep-2021</p> <p>Synopsis   The SWOG/Hope Foundation Impact Award is a funding program that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources from completed SWOG trials or be directly translatable to future clinical trials in SWOG and the National Clinical Trials Network (NCTN). These studies may involve scientific risk but potentially lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research. It is expected that support via this mechanism will lead to subsequent extramural support from other sources, and will be a metric of success for this grant program. In addition, publications citing SWOG and The Hope Foundation will be further metrics for success.</p>				
070207	<a href="#">Michelson Prizes</a>	Human Vaccines Project		18-Jul-2021	150,000 USD
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:michelsonprizes@humanvaccinesproject.org">michelsonprizes@humanvaccinesproject.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   18-Jul-2021</p> <p>Synopsis   The Michelson Prizes: Next Generation Grants are \$150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery and immunotherapy research for major global diseases.</p>				
033209	<a href="#">HD Human Biology Project - HDSA Research Fellowship</a>	Huntington's Disease Society of America, Inc.		09-Jul-2021	150,000 USD
	<p>Contact Name   Dr. George Yohrling, Senior Director of Mission and Scientific Affairs</p> <p>Contact Telephone   212-242-1968</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:GYohrling@hdsa.org">GYohrling@hdsa.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jul-2021</p> <p>Synopsis The HD Human Biology Project provides support for investigator-initiated research directed to better understand the biology of Huntington's disease (HD) as it occurs in humans. The research projects and observations resulting from them should have the potential to directly impact the lives of patients or help guide future drug development for HD.</p>				
000390	<a href="#">William James Award</a>		Institution of Engineering and Technology	30-Jul-2021	700 USD
	<p>Contact Name</p> <p>Contact Telephone +44 (0)1438 313311</p> <p>Contact Email <a href="mailto:postmaster@theiet.org">postmaster@theiet.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jul-2021</p> <p>Synopsis The award is presented to encourage, support and recognise the outstanding work of PhD or EngD students demonstrating a high level of commitment and advanced understanding of Biomedical Engineering.</p>				
020749	<a href="#">Primary Grants</a>		International Mechanical Diagnosis and Therapy Research Foundation	01-Jul-2021	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:info@imdtrf.org">info@imdtrf.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Jul-2021</p> <p>Synopsis This foundation is seeking grant applications to further research into the usefulness and limitations of Mechanical Diagnosis and Therapy (MDT). Consideration will be given to proposals examining basic and clinical sciences with the ultimate aim of improving the quality of care for musculoskeletal patients. New or experienced investigators are encouraged to apply. Preference will be given to proposals that include functional outcomes assessments. Proposals will be subjected to a peer-review process and only the highest quality projects will receive funding. The Primary Grant mechanism will fund up to \$50,000 USD for a 2 year proposal. Proposals to this mechanism must be original projects. Pilot study proposals are encouraged.</p>				
023519	<a href="#">Britton Chance Biomedical Optics Award</a>	International Society for Optics and Photonics		01-Jul-2021	2,000 USD
	<p>Contact Name</p> <p>Contact Telephone 360-676-3290</p> <p>Contact Email <a href="mailto:awards@spie.org">awards@spie.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jul-2021</p> <p>Synopsis The Britton Chance Biomedical Optics Award is presented annually in recognition of outstanding lifetime contributions to the field of biomedical optics through the development of innovative, high impact technologies.</p>				
041826	<a href="#">Biophotonics Technology Innovator Award</a>	International Society for Optics and Photonics		02-Jul-2021	2,000 USD
	<p>Contact Name</p> <p>Contact Telephone 360-676-3290</p> <p>Contact Email <a href="mailto:awards@spie.org">awards@spie.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 02-Jul-2021</p> <p>Synopsis The SPIE Biophotonics Technology Innovator Award is presented for extraordinary achievements in biophotonics technology development that show strong promise or potential impact in Biology, Medicine, and Biomedical Optics. The award consists of \$2,000.</p>				
081724	<a href="#">Therapeutic Area Contributions - Infectious Diseases Program</a>	Janssen Pharmaceuticals, Inc.		31-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 908-218-6095</p> <p>Contact Email</p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 31-May-2021 , 31-Jul-2021 , 30-Sep-2021 , 15-Nov-2021</p> <p>Synopsis Janssen Pharmaceuticals, Inc. makes charitable contributions to support therapeutic area initiatives. Applications are evaluated competitively with emphasis given to innovative programs with measurable outcomes that address disparities or unmet needs. The Infectious Diseases area of interest supports the following disease states: Hepatitis B; HIV / AIDS; Respiratory Infections; and Vaccines.</p>				
007466	<a href="#">Other Awards (Capital Funding, Equipment Grants, Clinical Support)</a>	Kendall (Kay) Leukaemia Fund		01-Jul-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 020 7410 7045.</p> <p>Contact Email <a href="mailto:info@kklf.org.uk">info@kklf.org.uk</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Jul-2021 Synopsis The Kay Kendall Leukaemia Fund will award capital funding, equipment grants, and clinical care grants for research on aspects of leukaemia.				
090535	<a href="#">Project Grants</a>	Kendall (Kay) Leukaemia Fund		01-Jul-2021	Not Specified
	Contact Name Contact Telephone 020 7410 0330 Contact Email <a href="mailto:info@kklf.org.uk">info@kklf.org.uk</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Jul-2021 Synopsis The Kay Kendall Leukaemia Fund awards grants for research on aspects of leukaemia and for relevant studies on related haematological malignancies.				
077770	<a href="#">Emerging Leader Award</a>	Mark Foundation for Cancer Research		26-Jul-2021	750,000 USD
	Contact Name Contact Telephone 646-866-5950 Contact Email <a href="mailto:info@themarkfoundation.org">info@themarkfoundation.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 26-Jul-2021 Synopsis The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.</p>			
067187	<a href="#">Neuroanesthesiology Fellowship (Minnesota)</a>	Mayo Clinic College of Medicine and Science		31-Jul-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Sandra K. Marzolf, Education Coordinator</p> <p>507-255-8731</p> <p><a href="mailto:marzolf.sandra@mayo.edu">marzolf.sandra@mayo.edu</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>31-Jul-2021</p> <p>Mayo Clinic offers a one-year fellowship training program in neuroanesthesiology at its campus in Rochester, Minnesota. This clinical fellowship has a great deal of flexibility to accommodate varied interests among fellows and is strongly rooted in Mayo's commitment to patient care, education, and research.</p>			
068239	<a href="#">Grants Program - Health &amp; Medical Research</a>	McGowan (William G.) Charitable Fund, Inc.		15-Jul-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p></p> <p>312-761-9503</p> <p><a href="mailto:info@williamgmcgowanfund.org">info@williamgmcgowanfund.org</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>15-Jul-2021 [LOI/Pre-App], 01-Sep-2021 , 15-Nov-2021 [LOI/Pre-App], 03-Jan-2022</p> <p>The McGowan Charitable Fund partners with institutions that advance cardiac-disease research and organizations that build healthy communities through innovative heart disease prevention programs.</p>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
079514	<a href="#">Tom Slick Research Awards in Consciousness</a>	Mind Science Foundation		28-Jul-2021	Not Specified
Contact Name   Mindy Cohen, Program & Communications Director Contact Telephone   210-821-6094 Contact Email   <a href="mailto:mcohen@mindsience.org">mcohen@mindsience.org</a> Sponsor Website   <a href="#">Link to sponsor website</a> Program URL   <a href="#">Link to program URL</a> Deadline Dates (ALL)   28-Jul-2021 Synopsis   Mind Science seeks to fund research that will lead to significant advancements in the science of consciousness and/or improvements in the health and well-being of humankind. Fields of inquiry include, but are not limited to: neuroscience, cognitive science, psychology, resiliency, physics, philosophy, biology, artificial intelligence, sleep and dream research, creativity, education, neuro-ethics, and experiential/subjective studies. Mind Science has chosen the “pitch” model for research funding because of its audience participation format, which emphasizes the importance of the pitch presenter’s excellent communication of important scientific work to the lay audience, who then cast their votes for best pitch and the grand prize of \$30,000. Finalists reaching the pitch competition are guaranteed \$15,000 in funding. In addition, each finalist will receive a stipend of \$1,500 to be used for registration and/or travel to a conference focused on increasing skills in science communication.					
078941	<a href="#">Research Grants - MPS II (Hunter Syndrome)</a>	National MPS Society, Inc.		15-Jul-2021 [LOI/Pre-App]	Not Specified
Contact Name   Contact Telephone   919-806-0101 Contact Email   <a href="mailto:grants@mpssociety.org">grants@mpssociety.org</a> Sponsor Website   Program URL   <a href="#">Link to program URL</a>					

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 15-Jul-2021 [LOI/Pre-App], 15-Sep-2021 , 15-Nov-2021 [LOI/Pre-App], 15-Jan-2022

Synopsis | The National MPS Society funds research that may lead to treatments for MPS and ML diseases and solicits applications for innovative research projects that involve clinical research, basic research and translational studies.

099011	<a href="#">NASPGHAN Foundation Innovations in Clinical Care Grant</a>	North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Foundation		01-Jul-2021	5,000 USD
--------	--	--	--	-------------	-----------

Contact Name	
Contact Telephone	215-641-9800
Contact Email	<a href="mailto:naspghan@naspghan.org">naspghan@naspghan.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jul-2021
Synopsis	The NASPGHAN Foundation Innovations in Clinical Care Grant is offered to encourage and support the development of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases by the clinically focused pediatric gastroenterologist. The Foundation will award up to two grants, each ranging from \$2,000 to \$5,000 for a one-year period.

088368	<a href="#">NASPGHAN Foundation/George Ferry Young Investigator Development Award</a>	North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Foundation		01-Jul-2021	150,000 USD
--------	---	--	--	-------------	-------------

Contact Name	
Contact Telephone	215-641-9800
Contact Email	<a href="mailto:naspghan@naspghan.org">naspghan@naspghan.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jul-2021</p> <p>Synopsis The NASPGHAN Foundation/NASPGHAN George Ferry Young Investigator Development Award is awarded to support a meritorious clinical, quality improvement, translational or basic science research project related to diseases of the gastrointestinal tract, liver, pancreas or nutritional disorders of children.</p>				
099010	<a href="#">NASPGHAN Foundation CPNP Nutrition Research Grant</a>	North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Foundation		01-Jul-2021	5,000 USD
	<p>Contact Name</p> <p>Contact Telephone 215-641-9800</p> <p>Contact Email <a href="mailto:naspghan@naspghan.org">naspghan@naspghan.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jul-2021</p> <p>Synopsis The NASPGHAN Foundation CPNP Nutrition Research Grant is a one-year award available to pediatric dietitians to support research activities that have the potential to advance the nutrition care of patients and families of children with nutritional disorders. The NASPGHAN Foundation will award grants ranging from \$500 to \$5000 for one year.</p>				
103653	<a href="#">NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Maldigestion/Malabsorption in Children</a>	North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Foundation		01-Jul-2021	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone 215-641-9800</p> <p>Contact Email <a href="mailto:naspghan@naspghan.org">naspghan@naspghan.org</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jul-2021			
	Synopsis	The NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Maldigestion/Malabsorption in Children will provide \$75,000 annually for two years (total \$150,000) for studies focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary.			
001939	<a href="#">NASPGHAN Foundation/Takeda Pharmaceutical Research Innovation Award</a>	North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Foundation		01-Jul-2021	150,000 USD
	Contact Name				
	Contact Telephone	215-641-9800			
	Contact Email	<a href="mailto:naspghan@naspghan.org">naspghan@naspghan.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jul-2021			
	Synopsis	This award will provide \$75,000 annually for two years for innovative, high-impact research in pediatric gastroenterology, hepatology and nutrition. The intent of this research award is to stimulate scientific inquiry in an area that is exceptionally innovative and has the potential to impact the field in a highly novel manner. Applicants at any career level may apply.			
001986	<a href="#">NASPGHAN Foundation/APGNN Susan Moyer Nursing Research Grant</a>	North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Foundation		01-Jul-2021	5,000 USD
	Contact Name				
	Contact Telephone	215-641-9800			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:naspghan@naspghan.org">naspghan@naspghan.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jul-2021</p> <p>Synopsis This one-year grant is available to pediatric gastroenterology, nutrition and hepatology nurses to support research activities that have the potential to advance nursing care of patients and families of children with gastrointestinal, hepatobiliary, pancreatic or nutritional disorders. Monies are awarded in support of a meritorious research projects to study the nursing care of families and children with pediatric gastrointestinal, hepatobiliary, pancreatic or nutritional disorders.</p>				
099007	<a href="#">NASPGHAN Foundation Mid-Level Career Development Award</a>	North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Foundation		01-Jul-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 215-641-9800</p> <p>Contact Email <a href="mailto:naspghan@naspghan.org">naspghan@naspghan.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jul-2021</p> <p>Synopsis The NASPGHAN Foundation Mid-Level Career Development Award is for NASPGHAN members pursuing research in pediatric gastroenterology, hepatology and nutrition and are at a mid-level in their career. This award will provide up to \$100,000 in direct funding for 2 years (\$50,000 per year).</p>				
002235	<a href="#">Program for Children with Special Health Care Needs</a>	Packard (Lucile) Foundation for Children's Health		23-Jul-2021 [LOI/Pre-App]	Not Specified
	Contact Name				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   650-497-8365</p> <p>Contact Email   <a href="mailto:info@lpfch.org">info@lpfch.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   23-Jul-2021 [LOI/Pre-App]</p> <p>Synopsis   The Foundation funds programs and projects that will contribute to improving California’s system of care for children with special health care needs and their families.</p>				
001069	<a href="#">Spinal Cord Research Foundation--Postdoctoral Fellowships Program</a>	Paralyzed Veterans of America		01-Jul-2021	100,000 USD
	<p>Contact Name   Cheryl Vines, M.S. Director of Research and Education</p> <p>Contact Telephone   805-439-2804</p> <p>Contact Email   <a href="mailto:cherylv@pva.org">cherylv@pva.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jul-2021</p> <p>Synopsis   Paralyzed Veterans of America provides fellowships for postdoctoral students in basic science, clinical applications, or design and development, intended to encourage training and specialization in the field of spinal cord research. The sponsor provides up to \$50,000 per year or up to \$100,000 for 2 years.</p>				
012623	<a href="#">Clinical Applications Grants</a>	Paralyzed Veterans of America		01-Jul-2021	150,000 USD
	<p>Contact Name   Lindsay Perlman</p> <p>Contact Telephone   202-416-7611</p> <p>Contact Email   <a href="mailto:LindsayP@pva.org">LindsayP@pva.org</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Jul-2021 Synopsis The Paralyzed Veterans of America Research Foundation supports innovative research and fellowships that improve the lives of those with spinal cord injury and disease (SCI/D). Clinical Applications grants support clinical and functional studies of the medical, psychosocial, and economic effects of spinal cord injury or disease, and / or interventions proposed to alleviate these effects.				
001563	<a href="#">Basic Science Research Grants</a>	Paralyzed Veterans of America		01-Jul-2021	150,000 USD
	Contact Name Lindsay Perlman Contact Telephone 202-416-7611 Contact Email <a href="mailto:LindsayP@pva.org">LindsayP@pva.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Jul-2021 Synopsis Basic Science research grants fund laboratory research in the basic sciences related to spinal cord injury or disease. The sponsor will provide up to \$75,000 per year or up to \$150,000 for 2 years.				
001067	<a href="#">Design and Development Grants</a>	Paralyzed Veterans of America		01-Jul-2021	Not Specified
	Contact Name Lindsay Perlman Contact Telephone 202-416-7611 Contact Email <a href="mailto:LindsayP@pva.org">LindsayP@pva.org</a> Sponsor Website <a href="#">Link to sponsor website</a>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jul-2021</p> <p>Synopsis Paralyzed Veterans of America provides funding to aid in the design and development of new or improved rehabilitative and assistive devices to improve function for individuals with spinal cord injury or disease. The sponsor will provide up to \$75,000 per year or up to \$150,000 for 2 years.</p>				
102065	<p><a href="#">Medical Education Grants: Local Level Educational Grants Program to Increase Awareness &amp; Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)</a></p>	Pfizer Pharmaceuticals		27-May-2021	20,000 USD
	<p>Contact Name Amanda Stein, Grant Officer</p> <p>Contact Telephone 212-733-2323</p> <p>Contact Email <a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 27-May-2021 , 29-Jul-2021 , 30-Sep-2021 , 28-Oct-2021</p> <p>Synopsis Pfizer requests applications focused on improving the care of patients on the local level with Transthyretin Cardiomyopathy (ATTR-CM).</p>				
016536	<p><a href="#">Garite Mini-Sabbatical Grants</a></p>	Pregnancy Foundation		01-Jul-2021	15,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-517-7068</p> <p>Contact Email <a href="mailto:foundation@smfm.org">foundation@smfm.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jul-2021</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Garite Mini-Sabbatical Grants allow recipients to gain or expand skills in clinical practice or research under the guidance of experts in the field of maternal-fetal medicine. The Foundation for SMFM awards up to \$15,000 in funding for mini-sabbatical grants each year to members of the Society for Maternal-Fetal Medicine (SMFM), including MFM fellows in ABOG-approved or DO-approved MFM fellowship programs.			
077263	<a href="#">Medical Research Grant</a>	Progeria Research Foundation		01-Jul-2021	75,000 USD
	Contact Name				
	Contact Telephone	978- 535-2594			
	Contact Email	<a href="mailto:researchgrants@progeriaresearch.org">researchgrants@progeriaresearch.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jul-2021 , 01-Oct-2021			
	Synopsis	The Progeria Research Foundation (PRF) is a driving force worldwide in finding treatments and the cure for Progeria and its aging-related disorders, including heart disease. The PRF invites qualified scientists with faculty appointments or the equivalent to submit applications for the 2021 grant cycle. Awards are typically for 1-2 years at a maximum of \$75,000 per year.			
058301	<a href="#">Research Grants</a>	PSC Partners Seeking a Cure		15-Jul-2021	Not Specified
	Contact Name				
	Contact Telephone	303-771-5227			
	Contact Email	<a href="mailto:contactus@pscpartners.org">contactus@pscpartners.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jul-2021			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	PSC Partners offers grants to conduct research that addresses an important and novel, basic or clinical research question related to PSC and closely associated diseases (such as inflammatory bowel diseases (IBD) and cholangiocarcinoma). The Research Grants Program seeks to encourage investigators to conduct research in promising new areas, with the goal that data generated will lead to federal (NIH) or external international funding.			
035003	<a href="#">Environmental Challenge</a>	RELX Group		04-Jul-2021	Not Specified
	Contact Name				
	Contact Telephone	+44 20 7166 5500			
	Contact Email	<a href="mailto:environmental.challenge@relx.com">environmental.challenge@relx.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	04-Jul-2021			
	Synopsis	The RELX Environmental Challenge is a skill-based competition in which participants are asked to submit proposals outlining innovative ideas that advance access to safe water and/or sanitation where access is presently at risk.			
070888	<a href="#">RPB Stein Innovation Awards</a>	Research to Prevent Blindness		15-Jun-2021 [LOI/Pre-App]	300,000 USD
	Contact Name	Pattie Moran			
	Contact Telephone	646-892-9566			
	Contact Email	<a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2021 [LOI/Pre-App], 01-Jul-2021			
	Synopsis	The RPB Stein Innovation (SI) Awards provide funds to two groups of researchers, both with a common goal of			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

understanding the visual system and the diseases that compromise its function. These SI Awards are intended to provide seed money to proposed high-risk/high-gain vision science research which is innovative, cutting-edge, and demonstrates out-of-the-box thinking.

039600	<a href="#">Catalyst Award for Stem Cell Research Approaches for Age-Related Macular Degeneration</a>	Research to Prevent Blindness		15-Jun-2021	300,000 USD
--------	---	-------------------------------	--	-------------	-------------

Contact Name	Pattie Moran
Contact Telephone	212-752-4333ex223
Contact Email	<a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jun-2021 , 01-Jul-2021
Synopsis	Research to Prevent Blindness (RPB) is partnering with: American Macular Degeneration Foundation (AMDF) Dr. H. James and Carole Free International Retinal Research Foundation (IRRF) to co-fund up to three (3) Catalyst Awards for Innovative Research Approaches for Age-Related Macular Degeneration (AMD). One (1) award will be made in partnership with AMDF, one (1) award with Dr. H. James and Carole Free, and one (1) award with IRRF. The \$300,000 grant is payable for up to three (3) years upon approval of a 14-month substantive progress report.

006942	<a href="#">Career Development Awards</a>	Research to Prevent Blindness		15-Jun-2021 [LOI/Pre-App]	350,000 USD
--------	---	-------------------------------	--	---------------------------	-------------

Contact Name	
Contact Telephone	646-892-9566
Contact Email	<a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p style="margin-left: 40px;">Deadline Dates (ALL)   15-Jun-2021 [LOI/Pre-App], 01-Jul-2021</p> <p style="margin-left: 80px;">Synopsis   The RPB Career Development Award (CDA) helps RPB-supported ophthalmology Chairs recruit promising young researchers to ophthalmology and support junior faculty who have demonstrated their potential for independent research. The \$350,000 grant is payable for up to four (4) years.</p>					
006934	<a href="#">Unrestricted Grants</a>	Research to Prevent Blindness		01-Jul-2021	115,000 USD
<p style="margin-left: 40px;">Contact Name   Pattie Moran</p> <p style="margin-left: 40px;">Contact Telephone   646-892-9566</p> <p style="margin-left: 40px;">Contact Email   <a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a></p> <p style="margin-left: 40px;">Sponsor Website   <a href="#">Link to sponsor website</a></p> <p style="margin-left: 40px;">Program URL   <a href="#">Link to program URL</a></p> <p style="margin-left: 40px;">Deadline Dates (ALL)   01-Jul-2021</p> <p style="margin-left: 80px;">Synopsis   Unrestricted Grants provide opportunities for creative planning and maximum flexibility in developing and expanding eye research programs. These annual \$115,000 grants provide opportunities for creative planning that go beyond the scope of restricted project grants which scientists normally depend upon for their principal support.</p>					
006935	<a href="#">Challenge Grants</a>	Research to Prevent Blindness		01-Jul-2021	300,000 USD
<p style="margin-left: 40px;">Contact Name   Pattie Moran</p> <p style="margin-left: 40px;">Contact Telephone   212-752-4333</p> <p style="margin-left: 40px;">Contact Email   <a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a></p> <p style="margin-left: 40px;">Sponsor Website   <a href="#">Link to sponsor website</a></p> <p style="margin-left: 40px;">Program URL   <a href="#">Link to program URL</a></p> <p style="margin-left: 40px;">Deadline Dates (ALL)   01-Jul-2021</p>					

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis		Challenge Grants encourage the growth of newly-emerging eye research programs or recently-appointed department heads. The Challenge Grant is designed to enhance a department's environment and capability to conduct vision research, to facilitate collaborative studies of the visual system, and to attract researchers to the department			
006939	<a href="#">Physician-Scientist Award</a>		Research to Prevent Blindness	15-Jun-2021 [LOI/Pre-App]	300,000 USD
Contact Name		Pattie Moran			
Contact Telephone		212-752-4333			
Contact Email		<a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a>			
Sponsor Website		<a href="#">Link to sponsor website</a>			
Program URL		<a href="#">Link to program URL</a>			
Deadline Dates (ALL)		15-Jun-2021 [LOI/Pre-App], 01-Jul-2021			
Synopsis		The RPB Physician-Scientist Award promotes the clinical and/or basic research of clinicians, recognizing that the clinical scientist has difficulty competing against basic scientists for national-level grant support. The maximum award is \$300,000, payable in two payments.			
070892	<a href="#">RPB International Research Collaborators Award</a>		Research to Prevent Blindness	15-Jun-2021 [LOI/Pre-App]	75,000 USD
Contact Name		Pattie Moran			
Contact Telephone		646-892-9566			
Contact Email		<a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a>			
Sponsor Website		<a href="#">Link to sponsor website</a>			
Program URL		<a href="#">Link to program URL</a>			
Deadline Dates (ALL)		15-Jun-2021 [LOI/Pre-App], 01-Jul-2021			
Synopsis		The RPB International Research Collaborators Award promotes international collaborations through which			



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>collaborating researchers in the U.S. and outside the U.S. gain new knowledge and skills. These international collaborations have the potential to accelerate the development of treatments for blinding disorders, positively affecting large populations worldwide for years to come. This award of up to \$75,000 is available to researchers from any institution of higher education in the United States. A three- to six-month stay in the other country is expected by each researcher, with a minimum stay of three months.</p>			
095001	<a href="#">Innovative Research Award</a>	Rheumatology Research Foundation		01-Jun-2021	400,000 USD
		<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email <a href="mailto:foundation@rheumatology.org">foundation@rheumatology.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 , 01-Jul-2021</p> <p>Synopsis The Innovative Research Award provides independent academic investigators with the funding they need to pursue ideas that could lead to important breakthroughs in discovering new treatments and, one day, a cure. This award provides essential support for innovative studies focused on generating new insights into the cause, progression, treatment, and outcomes of rheumatic and musculoskeletal diseases. The award amount is up to \$400,000 for two years (maximum \$200,000 per year).</p>			
000622	<a href="#">Scientist Development Award</a>	Rheumatology Research Foundation		01-Jun-2021 [LOI/Pre-App]	50,000 USD
		<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email <a href="mailto:foundation@rheumatology.org">foundation@rheumatology.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 [LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis This award is designed for individuals in the early stages of their career (typically Fellows) or those without significant prior research experience who plan to embark on careers in rheumatic diseases. The purpose of this award is to provide support for a structured research training program for rheumatologists or health professionals in the field of rheumatology.</p>				
087954	<a href="#">Jacquot Research Establishment Fellowship</a>	Royal Australasian College of Physicians		12-Jul-2021	69,300 USD
	<p>Contact Name</p> <p>Contact Telephone +61 (02) 9256 5444</p> <p>Contact Email</p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jul-2021</p> <p>Synopsis The Jacquot Research Establishment Fellowship provides \$90,000 in support to assist the establishment of a career in nephrology research for a nephrologist who has completed a research higher degree in an area of relevance.</p>				
046418	<a href="#">Science &amp; SciLifeLab Prize for Young Scientists</a>	Science		15-Jul-2021	30,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-326-6417</p> <p>Contact Email <a href="mailto:SciLifeLabPrize@aaas.org">SciLifeLabPrize@aaas.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jul-2021</p> <p>Synopsis The Science &amp; SciLifeLab Prize for Young Scientists is awarded annually to one young scientist for outstanding life</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	science research for which he/she was awarded a doctoral degree in the previous two years. The topic of the entrant's thesis research must be in one of the following categories: Cell and Molecular Biology; Genomics, Proteomics and Systems Biology; Ecology and Environment; Molecular Medicine.				
036217	<a href="#">SFI Discover Programme Call</a>	Science Foundation Ireland		01-Jul-2021	363,000 USD
	Contact Name				
	Contact Telephone	+353 (0)1 607 3200			
	Contact Email	<a href="mailto:discover.programme@sfi.ie">discover.programme@sfi.ie</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jul-2021			
	Synopsis	The SFI Discover Programme Call 2021 is a key part of the SFI Education and Public Engagement activity. In line with SFI's 2025 Strategy: Shaping Our Future, the SFI Discover Programme Call aims to empower and inspire deep public engagement. The programme contributes to the themes of Top Talent, Tangible Benefits and A Cohesive Ecosystem. Through its core objectives, the SFI Discover Programme activity will contribute to growing opportunities for dialogue between science and the public it serves and to improving diversity and inclusion in science, through its aims to broaden participation both geographically and amongst less represented voices in science. Underpinning all of this is SFI's ambition to empower participation, grow talent and be a beacon of best practice in STEM education and public engagement, while always endeavouring to achieve this through the spirit of inspiration. As we continue to live through the Covid-19 pandemic, SFI is more conscious than ever of the importance of supporting the public to have access to and to understand the complex science underpinning crises such as this, in the context of their lives, their health, the health of their loved ones, and the impact it has on our collective future.			
103937	<a href="#">Simons Foundation Autism Research Initiative (SFARI) - Genomics of ASD: Pathways to Genetic Therapies</a>	Simons Foundation		06-Jul-2021	400,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 646-654-0066</p> <p>Contact Email <a href="mailto:sciencerfa@simonsfoundation.org">sciencerfa@simonsfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 06-Jul-2021</p> <p>Synopsis The Simons Foundation Autism Research Initiative (SFARI) has issued a request for applications (RFA), Genomics of ASD: Pathways to Genetic Therapies. Grants awarded through this RFA are intended to advance our understanding of the genetic basis of ASD and the molecular and cellular consequences of genetic risk, and to provide a foundation for the development of treatments for select genetically defined forms of the condition. Special emphasis is placed on the use of scalable methods, especially as applied to genes that are suitable targets for genetic therapies. The annual budget is between \$200,000 and \$400,000, inclusive of 20 percent indirect costs, for a period of two or three years.</p>				
066767	<a href="#">Grants Program</a>	Snee-Reinhardt Charitable Foundation		30-Jul-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 412-884-3626</p> <p>Contact Email <a href="mailto:info@snee-reinhardt.org">info@snee-reinhardt.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jul-2021</p> <p>Synopsis The sponsor supports organizations that foster transformative programs which best serve the local community as a whole in the areas of arts and culture, education, environmental, health and medical, human services, and religion.</p>				
067677	<a href="#">Grants Program</a>	The Gibbs Family Foundation		01-Jul-2021 [LOI/Pre-App]	10,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 773-332-0323</p> <p>Contact Email <a href="mailto:info@thegibbsfamilyfoundation.org">info@thegibbsfamilyfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jul-2021 [LOI/Pre-App], 01-Oct-2021</p> <p>Synopsis Currently, TGFF seeks to expand its services to the community, in particular individuals at risk of contracting or developing rare diseases such as infectious diseases, certain cancers, and neurological conditions (see a sample list of diseases funded by the organization). TGFF is implementing an outreach and educational program targeting that population in the Midwest: IL, IN, WI, MN, OH, and MI.</p>				
001193	<a href="#">E.W. Al Thrasher Awards</a>	Thrasher Research Fund		20-Jul-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 801-240-4753</p> <p>Contact Email</p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Jul-2021 [LOI/Pre-App], 29-Oct-2021</p> <p>Synopsis The purpose of the E.W. "Al" Thrasher Awards is to improve children's health through medical research, with an emphasis on projects that have the potential to translate into clinically meaningful results within a few years. The Fund awards grants two times per year, with no fixed number of awards given in each funding cycle or in each year.</p>				
056108	<a href="#">VHLA Research Grant Program</a>	VHL Family Alliance Fund for Cancer Research		15-Jul-2021 [LOI/Pre-App]	Not Specified

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Ilene Sussman</p> <p>Contact Telephone   617-277-5667 x4</p> <p>Contact Email   <a href="mailto:research@vhl.org">research@vhl.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jul-2021 [LOI/Pre-App], 26-Aug-2021</p> <p>Synopsis   VHLA's competitive research grant program is helping to elucidate the pathways involved in tumorigenesis including how to overcome the body signaling and response to what it perceives as a hypoxic (low oxygen) environment. The VHL Alliance is dedicated to research, education, and support to improve awareness, diagnosis, treatment, and quality of life for those affected by von Hippel-Lindau.</p>				

024768	<a href="#">Collaborative Research Grants</a>	Zoos Victoria		21-May-2021	Not Specified
	<p>Contact Name   Dr Michael Magrath, Senior Research Manager, Wildlife Conservation &amp; Science</p> <p>Contact Telephone   +61-3 9340 2752</p> <p>Contact Email   <a href="mailto:research@zoo.org.au">research@zoo.org.au</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   21-May-2021 , 23-Jul-2021 , 17-Sep-2021 , 12-Nov-2021</p> <p>Synopsis   Zoos Victoria welcomes collaborative research proposals. These could involve the use of Zoos Victoria resources, active collaboration with Zoos Victoria staff or independent research at one of Zoos Victoria's three properties: Melbourne Zoo, Werribee Open Range Zoo or Healesville Sanctuary.</p>				